[S02DA03, antipyrine, Antipyrine may increase the neuroexcitatory activities of Levofloxacin.]
[J01GA01, streptomycin, Levofloxacin may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[A02BX02, sucralfate, Sucralfate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01CG01, sulbactam, Levofloxacin may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01CA16, sulbenicillin, The serum concentration of Levofloxacin can be increased when it is combined with Sulbenicillin.]
[J01EC02, sulfadiazine, The therapeutic efficacy of Sulfadiazine can be increased when used in combination with Levofloxacin.]
[J01EC01, sulfamethoxazole, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Levofloxacin.]
[S01AB02, sulfisoxazole, The therapeutic efficacy of Sulfisoxazole can be increased when used in combination with Levofloxacin.]
[M01AB02, sulindac, Sulindac may increase the neuroexcitatory activities of Levofloxacin.]
[N05AL01, sulpiride, The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Levofloxacin.]
[A10BB04, glibornuride, The therapeutic efficacy of Glibornuride can be increased when used in combination with Levofloxacin.]
[A10BC01, glymidine, The therapeutic efficacy of Glymidine can be increased when used in combination with Levofloxacin.]
[M01AX04, apazone, Azapropazone may increase the neuroexcitatory activities of Levofloxacin.]
[L01BB02, mercaptopurine, The metabolism of Mercaptopurine can be decreased when combined with Levofloxacin.]
[J01CA15, talampicillin, The serum concentration of Levofloxacin can be increased when it is combined with Talampicillin.]
[L02BA01, tamoxifen, The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Levofloxacin.]
[N05CD07, temazepam, Temazepam may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Levofloxacin.]
[B01AE07, dabigatran etexilate, Levofloxacin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.]
[G03BA03, testosterone, Testosterone may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Tetrabenazine.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Tetracaine.]
[S03AA02, tetracycline, Tetracycline may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N05AE05, lurasidone, The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Levofloxacin.]
[N04BC07, apomorphine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Levofloxacin.]
[R03DA07, theobromine, The metabolism of Theobromine can be decreased when combined with Levofloxacin.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Levofloxacin.]
[P02CA02, thiabendazole, Thiabendazole may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Eribulin is combined with Levofloxacin.]
[R06AD03, thiethylperazine, Thiethylperazine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N05AC02, thioridazine, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Levofloxacin.]
[G04BE06, moxisylyte, Levofloxacin may decrease the excretion rate of Moxisylyte which could result in a higher serum level.]
[B03AB03, sodium ironedetate, Sodium feredetate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N05AL03, tiapride, Levofloxacin may decrease the excretion rate of Tiapride which could result in a higher serum level.]
[J01CA13, ticarcillin, The serum concentration of Levofloxacin can be increased when it is combined with Ticarcillin.]
[B01AC05, ticlopidine, Ticlopidine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[S01ED01, timolol, The risk or severity of QTc prolongation can be increased when Timolol is combined with Levofloxacin.]
[P01AB02, tinidazole, Tinidazole may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[S01AA12, tobramycin, Levofloxacin may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, The therapeutic efficacy of Tolazamide can be increased when used in combination with Levofloxacin.]
[V04CA01, tolbutamide, The therapeutic efficacy of Tolbutamide can be increased when used in combination with Levofloxacin.]
[M02AA21, tolmetin, Tolmetin may increase the neuroexcitatory activities of Levofloxacin.]
[N02AX02, tramadol, Tramadol may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Levofloxacin.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Tretinoin is combined with Levofloxacin.]
[S01BA05, triamcinolone, The risk or severity of tendinopathy can be increased when Triamcinolone is combined with Levofloxacin.]
[C03DB02, triamterene, Triamterene may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD05, triazolam, Triazolam may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C03AA06, trichlormethiazide, Trichlormethiazide may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[A16AX12, trientine, Levofloxacin may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[S01AD02, trifluridine, Trifluridine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[D07AC02, fluclorolone, The risk or severity of tendinopathy can be increased when Fluclorolone is combined with Levofloxacin.]
[R03BA07, mometasone, The risk or severity of tendinopathy can be increased when Mometasone is combined with Levofloxacin.]
[A03AA05, trimebutine, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Levofloxacin.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Levofloxacin.]
[N03AC02, trimethadione, The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Levofloxacin.]
[J01EA01, trimethoprim, Trimethoprim may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N06AA06, trimipramine, The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Levofloxacin.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Levofloxacin.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Levofloxacin.]
[L01FX04, ipilimumab, Levofloxacin may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Vandetanib.]
[R02AA14, oxyquinoline, Levofloxacin may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[A10BH05, linagliptin, The therapeutic efficacy of Linagliptin can be increased when used in combination with Levofloxacin.]
[J05AG05, rilpivirine, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Levofloxacin.]
[S01AA28, vancomycin, Levofloxacin may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Levofloxacin.]
[B01AF01, rivaroxaban, Levofloxacin may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Levofloxacin.]
[C08DA01, verapamil, Verapamil may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N06AX09, viloxazine, Levofloxacin may decrease the excretion rate of Viloxazine which could result in a higher serum level.]
[B03BA01, vitamin B12, Cyanocobalamin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[B01AA03, warfarin, The therapeutic efficacy of Warfarin can be increased when used in combination with Levofloxacin.]
[C03BA10, xipamide, Xipamide may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AF05, zuclopenthixol, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Zuclopenthixol.]
[L01EC01, vemurafenib, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Vemurafenib.]
[M05BA05, tiludronic acid, Tiludronic acid may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[B06AC02, icatibant, Levofloxacin may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[L01ED01, crizotinib, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Crizotinib.]
[A02BC04, rabeprazole, Rabeprazole may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Levofloxacin.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Ziprasidone.]
[G03AC10, drospirenone, Drospirenone may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AC02, deferiprone, Levofloxacin may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[S01LA01, verteporfin, Levofloxacin may increase the photosensitizing activities of Verteporfin.]
[N02BA01, aspirin, Acetylsalicylic acid may increase the neuroexcitatory activities of Levofloxacin.]
[L01EJ01, ruxolitinib, Levofloxacin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[G04BD07, tolterodine, The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Levofloxacin.]
[J01DH04, doripenem, Levofloxacin may decrease the excretion rate of Doripenem which could result in a higher serum level.]
[J02AC03, voriconazole, The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Levofloxacin.]
[S01FA01, atropine, The risk or severity of QTc prolongation can be increased when Atropine is combined with Levofloxacin.]
[M01CB03, auranofin, Auranofin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[H02AB11, prednylidene, The risk or severity of tendinopathy can be increased when Prednylidene is combined with Levofloxacin.]
[B03XA04, peginesatide, Levofloxacin may decrease the excretion rate of Peginesatide which could result in a higher serum level.]
[L01BC07, azacitidine, Azacitidine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[L04AX01, azathioprine, Azathioprine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[L01BC05, gemcitabine, Gemcitabine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01CA09, azlocillin, The serum concentration of Levofloxacin can be increased when it is combined with Azlocillin.]
[J01DF01, aztreonam, Aztreonam may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[M03BX01, baclofen, Baclofen may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[A08AA11, lorcaserin, Levofloxacin may decrease the excretion rate of Lorcaserin which could result in a higher serum level.]
[G04BD12, mirabegron, The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Levofloxacin.]
[L02BB04, enzalutamide, Levofloxacin may decrease the excretion rate of Enzalutamide which could result in a higher serum level.]
[A02AA05, magnesium silicate, Magnesium silicate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[H02AA01, aldosterone, The risk or severity of tendinopathy can be increased when Aldosterone is combined with Levofloxacin.]
[D02BA02, octinoxate, Levofloxacin may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[J05AE04, nelfinavir, The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Levofloxacin.]
[N04BD02, rasagiline, Levofloxacin may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[N02CC03, zolmitriptan, The metabolism of Zolmitriptan can be decreased when combined with Levofloxacin.]
[V09IX04, fluorodeoxyglucose F18, Levofloxacin may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Levofloxacin.]
[V08CA11, gadofosveset, Levofloxacin may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[A16AX08, teduglutide, Levofloxacin may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Bedaquiline.]
[C04AX11, bencyclane, The risk or severity of QTc prolongation can be increased when Bencyclane is combined with Levofloxacin.]
[A10BH04, alogliptin, The therapeutic efficacy of Alogliptin can be increased when used in combination with Levofloxacin.]
[A16AX09, glycerol phenylbutyrate, Levofloxacin may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.]
[C03AA01, bendroflumethiazide, Bendroflumethiazide may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX06, pomalidomide, Levofloxacin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N02BA10, benorilate, Benorilate may increase the neuroexcitatory activities of Levofloxacin.]
[A10BK02, canagliflozin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Levofloxacin.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Gemifloxacin.]
[A12CC09, magnesium orotate, Magnesium orotate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Levofloxacin.]
[A10AE05, insulin detemir, The therapeutic efficacy of Insulin detemir can be increased when used in combination with Levofloxacin.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Benzocaine.]
[A10BX05, pramlintide, The therapeutic efficacy of Pramlintide can be increased when used in combination with Levofloxacin.]
[J02AX04, caspofungin, The excretion of Levofloxacin can be decreased when combined with Caspofungin.]
[L03AA12, ancestim, Levofloxacin may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, Celecoxib may increase the neuroexcitatory activities of Levofloxacin.]
[A12CC05, magnesium aspartate, Magnesium aspartate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N04AC01, benztropine, The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Levofloxacin.]
[L01EC02, dabrafenib, The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Levofloxacin.]
[R02AX03, benzydamine, Benzydamine may increase the neuroexcitatory activities of Levofloxacin.]
[L01EE01, trametinib, Levofloxacin may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Benzyl alcohol.]
[V09AX05, florbetapir F-18, Levofloxacin may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[B03AB04, ferric hydroxide, Ferric hydroxide can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N06AX28, levomilnacipran, Levofloxacin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[J05AJ03, dolutegravir, The excretion of Levofloxacin can be decreased when combined with Dolutegravir.]
[C08EA02, bepridil, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Bepridil.]
[A10BJ03, lixisenatide, The therapeutic efficacy of Lixisenatide can be increased when used in combination with Levofloxacin.]
[C02KX04, macitentan, Levofloxacin may decrease the excretion rate of Macitentan which could result in a higher serum level.]
[N06AX26, vortioxetine, Levofloxacin may decrease the excretion rate of Vortioxetine which could result in a higher serum level.]
[G03AC08, etonogestrel, Etonogestrel may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[V03AE05, sucroferric oxyhydroxide, Iron sucrose can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J05AP08, sofosbuvir, Levofloxacin may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[A10BK01, dapagliflozin, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Levofloxacin.]
[C01CA27, droxidopa, Levofloxacin may decrease the excretion rate of Droxidopa which could result in a higher serum level.]
[N05CH03, tasimelteon, Levofloxacin may decrease the excretion rate of Tasimelteon which could result in a higher serum level.]
[L04AA32, apremilast, Levofloxacin may decrease the excretion rate of Apremilast which could result in a higher serum level.]
[L02BG02, formestane, Levofloxacin may decrease the excretion rate of Formestane which could result in a higher serum level.]
[S03BA03, betamethasone, The risk or severity of tendinopathy can be increased when Betamethasone is combined with Levofloxacin.]
[V03AB34, fomepizole, Levofloxacin may decrease the excretion rate of Fomepizole which could result in a higher serum level.]
[A10BJ04, albiglutide, The therapeutic efficacy of Albiglutide can be increased when used in combination with Levofloxacin.]
[L01ED02, ceritinib, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Ceritinib.]
[A03BA03, hyoscyamine, The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Levofloxacin.]
[B01AA07, acenocoumarol, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Levofloxacin.]
[N07XX08, tafamidis, The excretion of Levofloxacin can be decreased when combined with Tafamidis.]
[A10BK03, empagliflozin, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Levofloxacin.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[V09AB03, ioflupane I-123, Levofloxacin may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Levofloxacin may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Levofloxacin may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[N03AG01, valproic acid, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Valproic acid.]
[D07AB02, hydrocortisone butyrate, The risk or severity of tendinopathy can be increased when Hydrocortisone butyrate is combined with Levofloxacin.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Levofloxacin.]
[M05BA03, pamidronic acid, Pamidronic acid may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Levofloxacin.]
[V08AA01, diatrizoic acid, Diatrizoate may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[V08AA04, iothalamic acid, Diatrizoate may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[A16AX10, eliglustat, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Eliglustat.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[A10BJ05, dulaglutide, The therapeutic efficacy of Dulaglutide can be increased when used in combination with Levofloxacin.]
[V03AE08, ferric citrate, Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S03AA06, gentamicin, Levofloxacin may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[B01AA01, dicumarol, The therapeutic efficacy of Dicoumarol can be increased when used in combination with Levofloxacin.]
[B01AF03, edoxaban, Levofloxacin may decrease the excretion rate of Edoxaban which could result in a higher serum level.]
[N06AX11, mirtazapine, The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Levofloxacin.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Lenvatinib.]
[L01XH03, panobinostat, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Panobinostat.]
[N02BE01, acetaminophen, Acetaminophen may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[L01DC01, bleomycin, Bleomycin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[B01AA11, tioclomarol, The therapeutic efficacy of Tioclomarol can be increased when used in combination with Levofloxacin.]
[C01EB17, ivabradine, Ivabradine may increase the QTc-prolonging activities of Levofloxacin.]
[A06AD03, magnesium peroxide, Magnesium peroxide can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A10BF01, acarbose, The therapeutic efficacy of Acarbose can be increased when used in combination with Levofloxacin.]
[M02AA25, aceclofenac, Aceclofenac may increase the neuroexcitatory activities of Levofloxacin.]
[M01AB11, acemetacin, Acemetacin may increase the neuroexcitatory activities of Levofloxacin.]
[S01EC01, acetazolamide, Acetazolamide may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AE06, insulin degludec, The therapeutic efficacy of Insulin degludec can be increased when used in combination with Levofloxacin.]
[V03AB37, idarucizumab, Levofloxacin may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Levofloxacin.]
[L01XG03, ixazomib, Levofloxacin may decrease the excretion rate of Ixazomib which could result in a higher serum level.]
[A10BB31, acetohexamide, The therapeutic efficacy of Acetohexamide can be increased when used in combination with Levofloxacin.]
[G04CA01, alfuzosin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Levofloxacin.]
[M04AB05, lesinurad, Levofloxacin may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[M01AE16, alminoprofen, Alminoprofen may increase the neuroexcitatory activities of Levofloxacin.]
[N03AX23, brivaracetam, Levofloxacin may decrease the excretion rate of Brivaracetam which could result in a higher serum level.]
[N05BA08, bromazepam, Levofloxacin may decrease the excretion rate of Bromazepam which could result in a higher serum level.]
[N04BC01, bromocriptine, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Levofloxacin.]
[A02AD05, aluminum magnesium silicate, Almasilate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02AB03, aluminum phosphate, Aluminium phosphate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Levofloxacin.]
[C03CA02, bumetanide, Bumetanide may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Bupivacaine.]
[C07AA19, bupranolol, The risk or severity of QTc prolongation can be increased when Bupranolol is combined with Levofloxacin.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Buserelin is combined with Levofloxacin.]
[N05BE01, buspirone, Buspirone may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Arsenic trioxide.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Artemether.]
[M02AA03, clofezone, Rabeprazole may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Levofloxacin.]
[J01CE04, azidocillin, The serum concentration of Levofloxacin can be increased when it is combined with Azidocillin.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Levofloxacin.]
[J01CA06, bacampicillin, The serum concentration of Levofloxacin can be increased when it is combined with Bacampicillin.]
[L01EF02, ribociclib, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Ribociclib.]
[A07EC04, balsalazide, Balsalazide may increase the neuroexcitatory activities of Levofloxacin.]
[R03DA08, bamifylline, The metabolism of Bamifylline can be decreased when combined with Levofloxacin.]
[A06AH05, naldemedine, Levofloxacin may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Levofloxacin.]
[N06BC01, caffeine, The metabolism of Caffeine can be decreased when combined with Levofloxacin.]
[A10BX06, benfluorex, The therapeutic efficacy of Benfluorex can be increased when used in combination with Levofloxacin.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Oxybuprocaine.]
[P01CA02, benznidazole, Levofloxacin may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[J01XX08, linezolid, The excretion of Levofloxacin can be decreased when combined with Linezolid.]
[J05AF06, abacavir, Abacavir may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N07XX13, valbenazine, Levofloxacin may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[L01ED04, brigatinib, The excretion of Levofloxacin can be decreased when combined with Brigatinib.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Levofloxacin.]
[L01BC06, capecitabine, Capecitabine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[L01XX59, enasidenib, The excretion of Levofloxacin can be decreased when combined with Enasidenib.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Levofloxacin.]
[L01EF03, abemaciclib, The excretion of Abemaciclib can be decreased when combined with Levofloxacin.]
[C07AB07, bisoprolol, Bisoprolol may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J05AG03, efavirenz, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Levofloxacin.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, The risk or severity of tendinopathy can be increased when Budesonide is combined with Levofloxacin.]
[M01AB07, bumadizone, Bumadizone may increase the neuroexcitatory activities of Levofloxacin.]
[N06AA15, butriptyline, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Butriptyline.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Acetyldigoxin is combined with Levofloxacin.]
[A10BJ06, semaglutide, The therapeutic efficacy of Semaglutide can be increased when used in combination with Levofloxacin.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Capsaicin.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Ertugliflozin can be increased when used in combination with Levofloxacin.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Levofloxacin.]
[C09AA01, captopril, The excretion of Levofloxacin can be decreased when combined with Captopril.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Macimorelin.]
[L02BB05, apalutamide, Levofloxacin may decrease the excretion rate of Apalutamide which could result in a higher serum level.]
[N03AF01, carbamazepine, Levofloxacin may decrease the excretion rate of Carbamazepine which could result in a higher serum level.]
[J01CA03, carbenicillin, The serum concentration of Levofloxacin can be increased when it is combined with Carbenicillin.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Levofloxacin.]
[L04AA37, baricitinib, Levofloxacin may decrease the excretion rate of Baricitinib which could result in a higher serum level.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Encorafenib.]
[J01DD14, ceftibuten, Ceftibuten may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01GB14, plazomicin, Levofloxacin may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[C07AB08, celiprolol, The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Levofloxacin.]
[L01XX62, ivosidenib, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Ivosidenib.]
[P01BA07, tafenoquine, The excretion of Levofloxacin can be decreased when combined with Tafenoquine.]
[A16AX14, migalastat, Levofloxacin may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, Levofloxacin may decrease the excretion rate of Stiripentol which could result in a higher serum level.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Levofloxacin.]
[A10BB06, carbutamide, The therapeutic efficacy of Carbutamide can be increased when used in combination with Levofloxacin.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Chloroprocaine.]
[D08AE05, chloroxylenol, Levofloxacin may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[M01AC05, lornoxicam, Lornoxicam may increase the neuroexcitatory activities of Levofloxacin.]
[R03DA02, oxtriphylline, The metabolism of Oxtriphylline can be decreased when combined with Levofloxacin.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Inotersen is combined with Levofloxacin.]
[L01AD01, carmustine, Carmustine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[L01EX13, gilteritinib, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Gilteritinib.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Amifampridine.]
[A06AX05, prucalopride, Levofloxacin may decrease the excretion rate of Prucalopride which could result in a higher serum level.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Cibenzoline is combined with Levofloxacin.]
[B01AC23, cilostazol, The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Levofloxacin.]
[P02BX04, triclabendazole, The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Levofloxacin.]
[J01FA09, clarithromycin, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Clarithromycin.]
[N06BA14, solriamfetol, Levofloxacin may decrease the excretion rate of Solriamfetol which could result in a higher serum level.]
[N05BA09, clobazam, Clobazam may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[H02AB14, cloprednol, The risk or severity of tendinopathy can be increased when Cloprednol is combined with Levofloxacin.]
[V03AE07, calcium acetate, Calcium acetate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A12CC06, magnesium lactate, Magnesium lactate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V03AE02, sevelamer, Sevelamer can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[H02AB17, cortivazol, The risk or severity of tendinopathy can be increased when Cortivazol is combined with Levofloxacin.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01CF03, methicillin, The serum concentration of Levofloxacin can be increased when it is combined with Meticillin.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[L01EX15, pexidartinib, The excretion of Levofloxacin can be decreased when combined with Pexidartinib.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C03BX03, cicletanine, Cicletanine may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[L01EJ02, fedratinib, The excretion of Levofloxacin can be decreased when combined with Fedratinib.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Entrectinib.]
[N07XX11, pitolisant, Levofloxacin may increase the QTc-prolonging activities of Pitolisant.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Levofloxacin.]
[N04CX01, istradefylline, The excretion of Levofloxacin can be decreased when combined with Istradefylline.]
[C03AA09, cyclothiazide, Cyclothiazide may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AE03, insulin, regular, pork, The therapeutic efficacy of Insulin pork can be increased when used in combination with Levofloxacin.]
[J01XX09, daptomycin, Daptomycin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01DB01, cephalexin, Cephalexin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01DB09, cephradine, Cefradine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[H02AB13, deflazacort, The risk or severity of tendinopathy can be increased when Deflazacort is combined with Levofloxacin.]
[A16AX16, givosiran, Givosiran may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[M09AX08, golodirsen, Levofloxacin may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Levofloxacin.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Dexchlorpheniramine.]
[S01XA12, dexpanthenol, Levofloxacin may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[L01XX72, tazemetostat, The excretion of Levofloxacin can be decreased when combined with Tazemetostat.]
[J05AB16, remdesivir, The excretion of Levofloxacin can be decreased when combined with Remdesivir.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Levofloxacin.]
[R02AA03, dichlorobenzyl alcohol, Levofloxacin may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, Levofloxacin may decrease the excretion rate of Dienogest which could result in a higher serum level.]
[L01XD01, porfimer sodium, Levofloxacin may increase the photosensitizing activities of Porfimer sodium.]
[M01AH02, rofecoxib, Rofecoxib may increase the neuroexcitatory activities of Levofloxacin.]
[C08CA16, clevidipine, Levofloxacin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C01BD07, dronedarone, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Dronedarone.]
[V03AE03, lanthanum carbonate, Lanthanum carbonate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S03AA08, chloramphenicol, The excretion of Levofloxacin can be decreased when combined with Chloramphenicol.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Levofloxacin.]
[L01EH03, tucatinib, The excretion of Levofloxacin can be decreased when combined with Tucatinib.]
[L01EX17, capmatinib, The excretion of Levofloxacin can be decreased when combined with Capmatinib.]
[D07XB03, fluprednidene, The risk or severity of tendinopathy can be increased when Fluprednidene is combined with Levofloxacin.]
[M01AC04, droxicam, Droxicam may increase the neuroexcitatory activities of Levofloxacin.]
[L01EX19, ripretinib, The excretion of Levofloxacin can be decreased when combined with Ripretinib.]
[V08CA05, mangafodipir, Levofloxacin may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[L01EX22, selpercatinib, The excretion of Levofloxacin can be decreased when combined with Selpercatinib.]
[M02AA27, dexketoprofen, Dexketoprofen may increase the neuroexcitatory activities of Levofloxacin.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Dyclonine.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Ebastine is combined with Levofloxacin.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Levofloxacin.]
[M09AX10, risdiplam, The serum concentration of Levofloxacin can be increased when it is combined with Risdiplam.]
[P01BA01, chloroquine, The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Levofloxacin.]
[L01EX23, pralsetinib, The excretion of Levofloxacin can be decreased when combined with Pralsetinib.]
[C03AA04, chlorothiazide, Chlorothiazide may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AB04, chlorpheniramine, The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with Levofloxacin.]
[N05AA01, chlorpromazine, The risk or severity of QTc prolongation can be increased when Chlorpromazine is combined with Levofloxacin.]
[A10BB02, chlorpropamide, The therapeutic efficacy of Chlorpropamide can be increased when used in combination with Levofloxacin.]
[N05AF03, chlorprothixene, The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Levofloxacin.]
[C03BA04, chlorthalidone, Chlorthalidone may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BB03, chlorzoxazone, Chlorzoxazone may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N02BA07, ethenzamide, Ethenzamide may increase the neuroexcitatory activities of Levofloxacin.]
[N02BA03, choline salicylate, Levofloxacin may decrease the excretion rate of Choline salicylate which could result in a higher serum level.]
[M01AB08, etodolac, Etodolac may increase the neuroexcitatory activities of Levofloxacin.]
[M02AA06, etofenamate, Etofenamate may increase the neuroexcitatory activities of Levofloxacin.]
[B06AC06, berotralstat, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Berotralstat.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Levofloxacin.]
[M01AX25, chondroitin sulfates, Levofloxacin may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[J05AJ04, cabotegravir, The excretion of Levofloxacin can be decreased when combined with Cabotegravir.]
[V03AF12, trilaciclib, The excretion of Levofloxacin can be decreased when combined with Trilaciclib.]
[N03AX10, felbamate, The risk or severity of QTc prolongation can be increased when Felbamate is combined with Levofloxacin.]
[M01AE05, fenbufen, Fenbufen may increase the neuroexcitatory activities of Levofloxacin.]
[N06BA10, fenethylline, The metabolism of Fenethylline can be decreased when combined with Levofloxacin.]
[C01CA19, fenoldopam, Fenoldopam may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[V08CA07, ferric ammonium citrate, Ferric ammonium citrate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V03AB31, prussian blue insoluble, Prussian blue can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AB02, iron sucrose, Iron sucrose can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA05, ferrous chloride, Ferrous chloride can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA02, ferrous fumarate, Ferrous fumarate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA03, ferrous gluconate, Ferrous gluconate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA06, ferrous succinate, Ferrous succinate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA07, ferrous sulfate, Ferrous sulfate anhydrous can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01DD15, cefdinir, Cefdinir may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Flumequine is combined with Levofloxacin.]
[R03BA03, flunisolide, The risk or severity of tendinopathy can be increased when Flunisolide is combined with Levofloxacin.]
[S02BA08, fluocinolone acetonide, The risk or severity of tendinopathy can be increased when Fluocinolone acetonide is combined with Levofloxacin.]
[S01JA01, fluorescein, The excretion of Levofloxacin can be decreased when combined with Fluorescein.]
[N02BG07, flupirtine, Levofloxacin may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Levofloxacin.]
[A10AF01, insulin, regular, human, The therapeutic efficacy of Insulin human can be increased when used in combination with Levofloxacin.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Levofloxacin.]
[B03AB10, ferric maltol, Ferric maltol can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02BA01, cimetidine, The serum concentration of Levofloxacin can be increased when it is combined with Cimetidine.]
[V08CA04, gadoteridol, Gadoteridol may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N07CA02, cinnarizine, The risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Levofloxacin.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Levofloxacin.]
[S03AA07, ciprofloxacin, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Levofloxacin.]
[L01XA01, cisplatin, Levofloxacin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06AB04, citalopram, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Citalopram.]
[C03DA05, finerenone, Finerenone may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Levofloxacin is combined with Fexinidazole.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Mobocertinib.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Clemastine.]
[M01AG01, mefenamic acid, Mefenamic acid may increase the neuroexcitatory activities of Levofloxacin.]
[A10BB12, glimepiride, The therapeutic efficacy of Glimepiride can be increased when used in combination with Levofloxacin.]
[A10BB08, gliquidone, The therapeutic efficacy of Gliquidone can be increased when used in combination with Levofloxacin.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Levofloxacin.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The risk or severity of QTc prolongation can be increased when Pacritinib is combined with Levofloxacin.]
[N06AA04, clomipramine, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Clomipramine.]
[N03AE01, clonazepam, Clonazepam may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J05AH02, oseltamivir, Oseltamivir may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[A10BX16, tirzepatide, The therapeutic efficacy of Tirzepatide can be increased when used in combination with Levofloxacin.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[A04AA01, ondansetron, The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Levofloxacin.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Granisetron is combined with Levofloxacin.]
[J01CF02, cloxacillin, The serum concentration of Levofloxacin can be increased when it is combined with Cloxacillin.]
[N05AH02, clozapine, The risk or severity of QTc prolongation can be increased when Clozapine is combined with Levofloxacin.]
[A10BX01, guar gum, The therapeutic efficacy of Guar gum can be increased when used in combination with Levofloxacin.]
[A10BK06, sotagliflozin, The therapeutic efficacy of Sotagliflozin can be increased when used in combination with Levofloxacin.]
[J01GB12, arbekacin, Levofloxacin may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Cocaine.]
[M01AX13, proquazone, Proquazone may increase the neuroexcitatory activities of Levofloxacin.]
[R05DA04, codeine, The excretion of Levofloxacin can be decreased when combined with Codeine.]
[J01CA18, hetacillin, The serum concentration of Levofloxacin can be increased when it is combined with Hetacillin.]
[M04AC01, colchicine, Levofloxacin may decrease the excretion rate of Colchicine which could result in a higher serum level.]
[J01XB01, colistin, Levofloxacin may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[A02AD04, hydrotalcite, Hydrotalcite can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Desflurane is combined with Levofloxacin.]
[A04AA03, tropisetron, Levofloxacin may decrease the excretion rate of Tropisetron which could result in a higher serum level.]
[A10BX03, nateglinide, The therapeutic efficacy of Nateglinide can be increased when used in combination with Levofloxacin.]
[N02BA16, imidazole-2-hydroxybenzoate, Imidazole salicylate may increase the neuroexcitatory activities of Levofloxacin.]
[H01AC03, mecasermin, The therapeutic efficacy of Mecasermin can be increased when used in combination with Levofloxacin.]
[A10AE04, insulin glargine, The therapeutic efficacy of Insulin glargine can be increased when used in combination with Levofloxacin.]
[J01FA15, telithromycin, The risk or severity of QTc prolongation can be increased when Telithromycin is combined with Levofloxacin.]
[R03BA08, ciclesonide, The risk or severity of tendinopathy can be increased when Ciclesonide is combined with Levofloxacin.]
[B01AC10, indobufen, Indobufen may increase the neuroexcitatory activities of Levofloxacin.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Levofloxacin.]
[J05AB14, valganciclovir, Levofloxacin may decrease the excretion rate of Valganciclovir which could result in a higher serum level.]
[J05AF09, emtricitabine, The excretion of Levofloxacin can be decreased when combined with Emtricitabine.]
[C05BB03, invert sugar, Levofloxacin may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Levofloxacin may decrease the excretion rate of Iodixanol which could result in a higher serum level.]
[V08AB05, iopromide, Levofloxacin may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Levofloxacin may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Levofloxacin may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, Valdecoxib may increase the neuroexcitatory activities of Levofloxacin.]
[N02CC05, almotriptan, Almotriptan may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[M01AH04, parecoxib, Parecoxib may increase the neuroexcitatory activities of Levofloxacin.]
[J02AC02, itraconazole, The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Levofloxacin.]
[S01AD03, acyclovir, Acyclovir may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Emedastine is combined with Levofloxacin.]
[N05BA10, ketazolam, Levofloxacin may decrease the excretion rate of Ketazolam which could result in a higher serum level.]
[M01AA06, kebuzone, Kebuzone may increase the neuroexcitatory activities of Levofloxacin.]
[L01EA01, imatinib, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Imatinib.]
[J02AC04, posaconazole, The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Levofloxacin.]
[C08CA09, lacidipine, The risk or severity of QTc prolongation can be increased when Lacidipine is combined with Levofloxacin.]
[N03AX09, lamotrigine, The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Levofloxacin.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Levofloxacin.]
[S01BA03, cortisone, The risk or severity of tendinopathy can be increased when Cortisone is combined with Levofloxacin.]
[N07BC04, lofexidine, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Lofexidine.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Levofloxacin.]
[M01AB09, lonazolac, Lonazolac may increase the neuroexcitatory activities of Levofloxacin.]
[M02AA31, loxoprofen, Loxoprofen may increase the neuroexcitatory activities of Levofloxacin.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C09AA03, lisinopril, Lisinopril may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[A02AD02, magaldrate, Magaldrate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A06AD01, magnesium carbonate, Magnesium carbonate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[H02AB15, meprednisone, The risk or severity of tendinopathy can be increased when Meprednisone is combined with Levofloxacin.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Mequitazine is combined with Levofloxacin.]
[J01DH02, meropenem, Meropenem may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Levofloxacin.]
[J01CA14, methampicillin, The serum concentration of Levofloxacin can be increased when it is combined with Metampicillin.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Levofloxacin.]
[C03DA04, eplerenone, Eplerenone may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD03, metylperon, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Melperone.]
[C03AA07, cyclopenthiazide, Cyclopenthiazide may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BF02, miglitol, The therapeutic efficacy of Miglitol can be increased when used in combination with Levofloxacin.]
[J05AF07, tenofovir disoproxil, Tenofovir disoproxil may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[S01XA18, cyclosporine, The serum concentration of Cyclosporine can be increased when it is combined with Levofloxacin.]
[R06AX02, cyproheptadine, The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Levofloxacin.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Levofloxacin.]
[M02AA02, mofebutazone, Mofebutazone may increase the neuroexcitatory activities of Levofloxacin.]
[M01AX22, morniflumate, Morniflumate may increase the neuroexcitatory activities of Levofloxacin.]
[C03XA02, conivaptan, Conivaptan may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE09, vardenafil, The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Levofloxacin.]
[M01AH05, etoricoxib, Etoricoxib may increase the neuroexcitatory activities of Levofloxacin.]
[L01AX04, dacarbazine, Dacarbazine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[M01AX01, nabumetone, Nabumetone may increase the neuroexcitatory activities of Levofloxacin.]
[N07BB05, nalmefene, Levofloxacin may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[S01GX04, nedocromil, Nedocromil may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N06AX06, nefazodone, Levofloxacin may decrease the excretion rate of Nefazodone which could result in a higher serum level.]
[C01DX16, nicorandil, Levofloxacin may decrease the excretion rate of Nicorandil which could result in a higher serum level.]
[L02BB02, nilutamide, Nilutamide may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C01CA23, theodrenaline, The metabolism of Theodrenaline can be decreased when combined with Levofloxacin.]
[M03AC11, cisatracurium, Levofloxacin may increase the neuromuscular blocking activities of Cisatracurium.]
[B01AX05, fondaparinux, Fondaparinux may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N06AB10, escitalopram, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Escitalopram.]
[G04BD08, solifenacin, The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Levofloxacin.]
[A07EC03, olsalazine, Olsalazine may increase the neuroexcitatory activities of Levofloxacin.]
[N06AA01, desipramine, The risk or severity of QTc prolongation can be increased when Desipramine is combined with Levofloxacin.]
[H01BA02, desmopressin, Desmopressin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[D07XC02, desoximetasone, The risk or severity of tendinopathy can be increased when Desoximetasone is combined with Levofloxacin.]
[V04CH02, indigo carmine, Levofloxacin may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[H02AA03, desoxycorticosterone, The risk or severity of tendinopathy can be increased when Desoxycortone is combined with Levofloxacin.]
[J01DH03, ertapenem, Ertapenem may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Levofloxacin.]
[M01AE12, oxaprozin, Oxaprozin may increase the neuroexcitatory activities of Levofloxacin.]
[S03BA01, dexamethasone, The risk or severity of tendinopathy can be increased when Dexamethasone is combined with Levofloxacin.]
[N06BA02, dextroamphetamine, Amphetamine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C01DA05, pentaerythritol tetranitrate, Levofloxacin may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[C04AD01, pentifylline, The metabolism of Pentifylline can be decreased when combined with Levofloxacin.]
[P03AC04, permethrin, Levofloxacin may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, Diazepam may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01CE05, phenethicillin, The serum concentration of Levofloxacin can be increased when it is combined with Pheneticillin.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Phenol.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Cinchocaine.]
[R05DA08, pholcodine, Levofloxacin may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[S01EC02, dichlorphenamide, Diclofenamide may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC03, diclofenac, Diclofenac may increase the neuroexcitatory activities of Levofloxacin.]
[J01CF01, dicloxacillin, The serum concentration of Levofloxacin can be increased when it is combined with Dicloxacillin.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Levofloxacin.]
[A03AA07, dicyclomine, Dicyclomine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J05AF02, didanosine, Didanosine can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A03AX04, pinaverium, The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Levofloxacin.]
[A10BG03, pioglitazone, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Levofloxacin.]
[L01EB02, erlotinib, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Erlotinib.]
[C03CA03, piretanide, Piretanide may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CA03, isradipine, The risk or severity of QTc prolongation can be increased when Isradipine is combined with Levofloxacin.]
[D07XC04, diflucortolone, The risk or severity of tendinopathy can be increased when Difluocortolone is combined with Levofloxacin.]
[N02BA11, diflunisal, Diflunisal may increase the neuroexcitatory activities of Levofloxacin.]
[C01AA04, digitoxin, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Levofloxacin.]
[C01AA05, digoxin, Levofloxacin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N02AA03, hydromorphone, Hydromorphone may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[L04AX04, lenalidomide, Lenalidomide may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J05AE08, atazanavir, The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Levofloxacin.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Levofloxacin.]
[H03BC01, potassium perchlorate, Levofloxacin may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.]
[V03AB04, pralidoxime, Pralidoxime may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Pramocaine.]
[C08DB01, diltiazem, The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Levofloxacin.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Levofloxacin.]
[V03AB09, dimercaprol, Levofloxacin may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[M02AX03, dimethyl sulfoxide, Dimethyl sulfoxide may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N06BC02, propentofylline, The metabolism of Propentofylline can be decreased when combined with Levofloxacin.]
[J01CE03, propicillin, The serum concentration of Levofloxacin can be increased when it is combined with Propicillin.]
[N02BB04, propyphenazone, Propyphenazone may increase the neuroexcitatory activities of Levofloxacin.]
[M01AB14, proglumetacin, Proglumetacin may increase the neuroexcitatory activities of Levofloxacin.]
[G02AD02, dinoprostone, The excretion of Levofloxacin can be decreased when combined with Dinoprostone.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Proparacaine.]
[R03DA03, proxyphylline, The metabolism of Proxyphylline can be decreased when combined with Levofloxacin.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Diphenhydramine.]
[C09AA06, quinapril, Quinapril can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A03FA02, cisapride, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Cisapride.]
[S01AX06, resorcinol, Levofloxacin may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Disopyramide.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Levofloxacin.]
[S02AA12, rifamycin SV, The excretion of Levofloxacin can be decreased when combined with Rifamycin.]
[N05AX08, risperidone, The risk or severity of QTc prolongation can be increased when Risperidone is combined with Levofloxacin.]
[R06AE09, levocetirizine, The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Levofloxacin.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Ropivacaine.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Levofloxacin.]
[L01EX01, sunitinib, The therapeutic efficacy of Sunitinib can be increased when used in combination with Levofloxacin.]
[C03XA01, tolvaptan, Tolvaptan may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XG01, bortezomib, The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Levofloxacin.]
[G04BE08, tadalafil, Tadalafil may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[S01BC05, ketorolac, Ketorolac may increase the neuroexcitatory activities of Levofloxacin.]
[C01EB18, ranolazine, The risk or severity of QTc prolongation can be increased when Ranolazine is combined with Levofloxacin.]
[N02BA06, salsalate, Salsalate may increase the neuroexcitatory activities of Levofloxacin.]
[R03AC12, salmeterol, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Levofloxacin.]
[H05BA01, salmon calcitonin, Salmon calcitonin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C01CA07, dobutamine, Dobutamine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Domperidone.]
[C01CA04, dopamine, Dopamine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N06AA16, dothiepin, The risk or severity of QTc prolongation can be increased when Dosulepin is combined with Levofloxacin.]
[N06AA12, doxepin, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Levofloxacin.]
[J01AA02, doxycycline, Doxycycline may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[R06AA09, doxylamine, The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Levofloxacin.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Levofloxacin.]
[N05AD08, droperidol, The risk or severity of QTc prolongation can be increased when Droperidol is combined with Levofloxacin.]
[A08AA10, sibutramine, Sibutramine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[A12CA02, sodium sulfate, Levofloxacin may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[R03DA01, dyphylline, The metabolism of Dyphylline can be decreased when combined with Levofloxacin.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Sultopride.]
[N02CC01, sumatriptan, Sumatriptan may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[V04CX07, edrophonium, Edrophonium may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C07AB13, talinolol, The risk or severity of QTc prolongation can be increased when Talinolol is combined with Levofloxacin.]
[H01AA01, corticotropin, The risk or severity of tendinopathy can be increased when Corticotropin is combined with Levofloxacin.]
[J01CG02, tazobactam, The excretion of Levofloxacin can be decreased when combined with Tazobactam.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Temafloxacin.]
[J01CA17, temocillin, The serum concentration of Levofloxacin can be increased when it is combined with Temocillin.]
[L01AX03, temozolomide, Temozolomide may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[M01AC02, tenoxicam, Tenoxicam may increase the neuroexcitatory activities of Levofloxacin.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Terodiline.]
[C09AA02, enalapril, The excretion of Levofloxacin can be decreased when combined with Enalapril.]
[M01AG02, tolfenamic acid, Tolfenamic acid may increase the neuroexcitatory activities of Levofloxacin.]
[N06AG03, toloxatone, Levofloxacin may decrease the excretion rate of Toloxatone which could result in a higher serum level.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Levofloxacin.]
[N03AX11, topiramate, Topiramate may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Toremifene.]
[C03CA04, torsemide, Torasemide may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CC01, chloral hydrate, Levofloxacin may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.]
[H02CA01, trilostane, The risk or severity of tendinopathy can be increased when Trilostane is combined with Levofloxacin.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Levofloxacin.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Levofloxacin.]
[S01GX10, epinastine, The risk or severity of QTc prolongation can be increased when Epinastine is combined with Levofloxacin.]
[N06AX16, venlafaxine, Venlafaxine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[B05XA12, zinc chloride, Zinc chloride can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B05XA18, zinc sulfate, Zinc sulfate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M01AB04, zomepirac, Zomepirac may increase the neuroexcitatory activities of Levofloxacin.]
[N03AX15, zonisamide, Zonisamide may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AB06, insulin glulisine, human, The therapeutic efficacy of Insulin glulisine can be increased when used in combination with Levofloxacin.]
[L01XA02, carboplatin, Carboplatin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C02AC02, guanfacine, Guanfacine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C01BG01, moricizine, The risk or severity of QTc prolongation can be increased when Moricizine is combined with Levofloxacin.]
[L03AX05, pidotimod, Levofloxacin may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[S01AA17, erythromycin, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Levofloxacin.]
[N05CD04, estazolam, Levofloxacin may decrease the excretion rate of Estazolam which could result in a higher serum level.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[G03CA03, estradiol, Estradiol may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J04AK02, ethambutol, Ethambutol may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[R03BA09, fluticasone furoate, The risk or severity of tendinopathy can be increased when Fluticasone furoate is combined with Levofloxacin.]
[R03BA05, fluticasone, The risk or severity of tendinopathy can be increased when Fluticasone is combined with Levofloxacin.]
[V08CA03, gadodiamide, Gadodiamide may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Ibutilide.]
[N03AD01, ethosuximide, The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Levofloxacin.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Meloxicam.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Etidocaine.]
[N01AX07, etomidate, Etomidate may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Levofloxacin.]
[L04AD02, tacrolimus, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Levofloxacin.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Levofloxacin.]
[R06AX11, astemizole, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Astemizole.]
[R06AX12, terfenadine, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Terfenadine.]
[P01AX07, trimetrexate, Levofloxacin may decrease the excretion rate of Trimetrexate which could result in a higher serum level.]
[N06AX12, bupropion, Levofloxacin may decrease the excretion rate of Bupropion which could result in a higher serum level.]
[N06AB08, fluvoxamine, Fluvoxamine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Encainide is combined with Levofloxacin.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Levofloxacin.]
[C10AA03, pravastatin, The excretion of Levofloxacin can be decreased when combined with Pravastatin.]
[M01CB01, gold sodium thiomalate, Levofloxacin may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, Levofloxacin may decrease the excretion rate of Dextran which could result in a higher serum level.]
[V03AF02, dexrazoxane, Dexrazoxane may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Levofloxacin.]
[A16AA01, levocarnitine, Levocarnitine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C08CA02, felodipine, The risk or severity of QTc prolongation can be increased when Felodipine is combined with Levofloxacin.]
[C08EA01, fendiline, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Fendiline.]
[M01AE04, fenoprofen, Fenoprofen may increase the neuroexcitatory activities of Levofloxacin.]
[N02AB03, fentanyl, Fentanyl may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Levofloxacin.]
[L01BB06, clofarabine, Clofarabine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N07AX03, cevimeline, Cevimeline may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[G04BD02, flavoxate, Levofloxacin may decrease the excretion rate of Flavoxate which could result in a higher serum level.]
[C01BC04, flecainide, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Flecainide.]
[N02BG04, floctafenine, Floctafenine may increase the neuroexcitatory activities of Levofloxacin.]
[J01CF05, floxacillin, The serum concentration of Levofloxacin can be increased when it is combined with Flucloxacillin.]
[J02AC01, fluconazole, The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Levofloxacin.]
[J02AX01, flucytosine, Flucytosine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[H02AA02, fludrocortisone, The risk or severity of tendinopathy can be increased when Fludrocortisone is combined with Levofloxacin.]
[V03AB25, flumazenil, Levofloxacin may decrease the excretion rate of Flumazenil which could result in a higher serum level.]
[D07XB01, flumethasone, The risk or severity of tendinopathy can be increased when Flumethasone is combined with Levofloxacin.]
[D07AC08, fluocinonide, The risk or severity of tendinopathy can be increased when Fluocinonide is combined with Levofloxacin.]
[H02AB03, fluocortolone, The risk or severity of tendinopathy can be increased when Fluocortolone is combined with Levofloxacin.]
[L01BC09, floxuridine, Floxuridine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[L01BC02, fluorouracil, The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Levofloxacin.]
[N06AB03, fluoxetine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Levofloxacin.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Flupentixol.]
[N05CD01, flurazepam, Flurazepam may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[S01BC04, flurbiprofen, Flurbiprofen may increase the neuroexcitatory activities of Levofloxacin.]
[N05AG01, fluspirilene, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Fluspirilene.]
[L02BB01, flutamide, Flutamide may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[S02AA17, fosfomycin, Fosfomycin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[L01BC03, tegafur, Levofloxacin may decrease the excretion rate of Tegafur which could result in a higher serum level.]
[C03CA01, furosemide, Furosemide may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CF04, eszopiclone, Eszopiclone may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Amisulpride.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Levofloxacin.]
[C08DA02, gallopamil, The risk or severity of QTc prolongation can be increased when Gallopamil is combined with Levofloxacin.]
[S01AD09, ganciclovir, Ganciclovir may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C10AB04, gemfibrozil, Levofloxacin may decrease the excretion rate of Gemfibrozil which could result in a higher serum level.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Degarelix is combined with Levofloxacin.]
[L01EA02, dasatinib, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Levofloxacin.]
[C01CA21, cafedrine, The metabolism of Cafedrine can be decreased when combined with Levofloxacin.]
[A10BJ02, liraglutide, The therapeutic efficacy of Liraglutide can be increased when used in combination with Levofloxacin.]
[N03AD03, methsuximide, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Levofloxacin.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Levofloxacin.]
[A10BB01, glyburide, The therapeutic efficacy of Glyburide can be increased when used in combination with Levofloxacin.]
[A10BB09, gliclazide, The therapeutic efficacy of Gliclazide can be increased when used in combination with Levofloxacin.]
[A10BB07, glipizide, The therapeutic efficacy of Glipizide can be increased when used in combination with Levofloxacin.]
[N05CM18, dexmedetomidine, Dexmedetomidine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C01BD04, dofetilide, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Dofetilide.]
[L01EX02, sorafenib, The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Levofloxacin.]
[C07AB09, esmolol, The risk or severity of QTc prolongation can be increased when Esmolol is combined with Levofloxacin.]
[M01CB04, aurothioglucose, Levofloxacin may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Levofloxacin may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[B01AA12, fluindione, The therapeutic efficacy of Fluindione can be increased when used in combination with Levofloxacin.]
[C09AA09, fosinopril, Fosinopril may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[S01EX01, guanethidine, Levofloxacin may decrease the excretion rate of Guanethidine which could result in a higher serum level.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Goserelin is combined with Levofloxacin.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Haloperidol.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Histrelin is combined with Levofloxacin.]
[N05AH04, quetiapine, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Quetiapine.]
[N06BX13, idebenone, Levofloxacin may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[A10AD05, insulin aspart, human, The therapeutic efficacy of Insulin aspart can be increased when used in combination with Levofloxacin.]
[M04AA01, allopurinol, Allopurinol may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C09CA01, losartan, The risk or severity of QTc prolongation can be increased when Losartan is combined with Levofloxacin.]
[B05CB03, magnesium citrate, Magnesium citrate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A12CC03, magnesium gluconate, Magnesium gluconate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[G03DC01, allylestrenol, Levofloxacin may decrease the excretion rate of Allylestrenol which could result in a higher serum level.]
[A07EC02, mesalamine, Mesalazine may increase the neuroexcitatory activities of Levofloxacin.]
[C01CE02, milrinone, Milrinone may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C08CA10, nilvadipine, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Nilvadipine.]
[M02AA26, nimesulide, Nimesulide may increase the neuroexcitatory activities of Levofloxacin.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Oxatomide.]
[C09AA04, perindopril, Perindopril may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C02DB02, hydralazine, Levofloxacin may decrease the excretion rate of Hydralazine which could result in a higher serum level.]
[C03AA03, hydrochlorothiazide, Hydrochlorothiazide may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[S02BA01, hydrocortisone, The risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Levofloxacin.]
[C03AA02, hydroflumethiazide, Hydroflumethiazide may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA17, potassium acetate, Levofloxacin may decrease the excretion rate of Potassium acetate which could result in a higher serum level.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Hydroxocobalamin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[G04BD06, propiverine, Levofloxacin may decrease the excretion rate of Propiverine which could result in a higher serum level.]
[P01BA02, hydroxychloroquine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Levofloxacin.]
[B05AA07, hetastarch, Levofloxacin may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Hydroxyzine.]
[R02AX02, ibuprofen, Ibuprofen may increase the neuroexcitatory activities of Levofloxacin.]
[B05XA08, sodium acetate, Levofloxacin may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[L01AA06, ifosfamide, Levofloxacin may decrease the excretion rate of Ifosfamide which could result in a higher serum level.]
[N06AA02, imipramine, The risk or severity of QTc prolongation can be increased when Imipramine is combined with Levofloxacin.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Terlipressin.]
[R01AD07, tixocortol, The risk or severity of tendinopathy can be increased when Tixocortol is combined with Levofloxacin.]
[M03BX02, tizanidine, The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Levofloxacin.]
[L01CE01, topotecan, The excretion of Topotecan can be decreased when combined with Levofloxacin.]
[C03BA11, indapamide, Indapamide may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC01, indomethacin, Indomethacin may increase the neuroexcitatory activities of Levofloxacin.]
[A16AX05, zinc acetate, Zinc acetate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A12CB02, zinc gluconate, Zinc gluconate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A11HA07, inositol, Levofloxacin may decrease the excretion rate of Inositol which could result in a higher serum level.]
[N06AX17, milnacipran, Levofloxacin may decrease the excretion rate of Milnacipran which could result in a higher serum level.]
[S01XA28, varenicline, Levofloxacin may decrease the excretion rate of Varenicline which could result in a higher serum level.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Articaine.]
[A10BH01, sitagliptin, The therapeutic efficacy of Sitagliptin can be increased when used in combination with Levofloxacin.]
[N05BA12, alprazolam, Alprazolam may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N05CH02, ramelteon, Ramelteon may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Buclizine is combined with Levofloxacin.]
[A10BH02, vildagliptin, The therapeutic efficacy of Vildagliptin can be increased when used in combination with Levofloxacin.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Anagrelide.]
[C03BA02, quinethazone, Quinethazone may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB01, ipecac, Levofloxacin may decrease the excretion rate of Ipecac which could result in a higher serum level.]
[G04BE01, alprostadil, The excretion of Levofloxacin can be decreased when combined with Alprostadil.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Levofloxacin.]
[J04AC01, isoniazid, Isoniazid may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J05AX05, inosine pranobex, Levofloxacin may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[A10BJ01, exenatide, The therapeutic efficacy of Exenatide can be increased when used in combination with Levofloxacin.]
[C01DA14, isosorbide mononitrate, Isosorbide mononitrate may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[D10BA01, isotretinoin, Isotretinoin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[S01AA24, kanamycin, Levofloxacin may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[A02AB01, aluminum hydroxide, Aluminum hydroxide can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N01AX03, ketamine, Levofloxacin may decrease the excretion rate of Ketamine which could result in a higher serum level.]
[B01AC22, prasugrel, Levofloxacin may decrease the excretion rate of Prasugrel which could result in a higher serum level.]
[J02AB02, ketoconazole, The risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Levofloxacin.]
[H02CA04, levoketoconazole, The excretion of Levofloxacin can be decreased when combined with Levoketoconazole.]
[N05AH03, olanzapine, The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Levofloxacin.]
[M02AA10, ketoprofen, Ketoprofen may increase the neuroexcitatory activities of Levofloxacin.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Mizolastine.]
[D10AX03, azelaic acid, Azelaic acid may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Levofloxacin.]
[M01AE11, tiaprofenic acid, Tiaprofenic acid may increase the neuroexcitatory activities of Levofloxacin.]
[C07AG01, labetalol, Labetalol may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Levofloxacin.]
[A06AD11, lactulose, The therapeutic efficacy of Lactulose can be decreased when used in combination with Levofloxacin.]
[A06AX03, lubiprostone, Lubiprostone may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C03CC01, ethacrynic acid, Etacrynic acid may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[J01CA11, amdinocillin, The serum concentration of Levofloxacin can be increased when it is combined with Amdinocillin.]
[J01CA08, amdinocillin pivoxil, The serum concentration of Levofloxacin can be increased when it is combined with Pivmecillinam.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Lidocaine.]
[C08EX01, lidoflazine, The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Levofloxacin.]
[S01AA21, amikacin, Levofloxacin may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[C03DB01, amiloride, Amiloride may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[A07DA03, loperamide, The risk or severity of QTc prolongation can be increased when Loperamide is combined with Levofloxacin.]
[N05BA06, lorazepam, Lorazepam may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[B05XA11, magnesium chloride, Magnesium chloride can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[G04BX01, magnesium hydroxide, Magnesium hydroxide can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A12CC10, magnesium oxide, Magnesium oxide can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V04CC02, magnesium sulfate, Magnesium sulfate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01BA05, pralatrexate, Levofloxacin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.]
[L01EA03, nilotinib, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Nilotinib.]
[V04CX04, mannitol, Mannitol may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA21, maprotiline, The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Levofloxacin.]
[C02BB01, mecamylamine, Mecamylamine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[M02AA18, meclofenamic acid, Meclofenamic acid may increase the neuroexcitatory activities of Levofloxacin.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Levofloxacin.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[N06DX01, memantine, Memantine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N02AB02, meperidine, Meperidine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Mepivacaine.]
[G04BX16, tiopronin, Levofloxacin may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Levofloxacin.]
[N05AX13, paliperidone, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Paliperidone.]
[A10BA02, metformin, The therapeutic efficacy of Metformin can be increased when used in combination with Levofloxacin.]
[A04AA04, dolasetron, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Levofloxacin.]
[N07BC02, methadone, The risk or severity of QTc prolongation can be increased when Methadone is combined with Levofloxacin.]
[N06BA03, methamphetamine, Levofloxacin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.]
[J05AF05, lamivudine, Lamivudine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[S01EC05, methazolamide, Methazolamide may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[H03BB02, methimazole, Methimazole may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[L01BA04, pemetrexed, Levofloxacin may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[L04AX03, methotrexate, Methotrexate may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N05AA02, methotrimeprazine, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Levofloxacin.]
[D05BA02, methoxsalen, Methoxsalen may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C03AA08, methyclothiazide, Methyclothiazide may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AB01, methyldopa, Methyldopa may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[V04CG05, methylene blue, Levofloxacin may decrease the excretion rate of Methylene blue which could result in a higher serum level.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be decreased when combined with Levofloxacin.]
[H02AB04, methylprednisolone, The risk or severity of tendinopathy can be increased when Methylprednisolone is combined with Levofloxacin.]
[D07AC14, methylprednisolone aceponate, The risk or severity of tendinopathy can be increased when Methylprednisolone aceponate is combined with Levofloxacin.]
[G03EK01, methyltestosterone, Levofloxacin may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.]
[A03FA01, metoclopramide, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Levofloxacin.]
[C03BA08, metolazone, Metolazone may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB02, metoprolol, Metoprolol may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Levofloxacin.]
[V04CD01, metyrapone, Metyrapone may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01CA10, mezlocillin, The serum concentration of Levofloxacin can be increased when it is combined with Mezlocillin.]
[N02BB03, aminopyrine, Aminophenazone may increase the neuroexcitatory activities of Levofloxacin.]
[N05CD08, midazolam, Midazolam may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[G03XB01, mifepristone, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Mifepristone.]
[J05AH01, zanamivir, Zanamivir may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01AA08, minocycline, The excretion of Levofloxacin can be decreased when combined with Minocycline.]
[L03AC01, aldesleukin, Aldesleukin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C01BD01, amiodarone, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Amiodarone.]
[N06AA09, amitriptyline, Levofloxacin may increase the QTc-prolonging activities of Amitriptyline.]
[A04AA05, palonosetron, Palonosetron may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[L04AB05, certolizumab pegol, Levofloxacin may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.]
[G04BA01, ammonium chloride, Levofloxacin may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.]
[L01EX03, pazopanib, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Pazopanib.]
[L04AA06, mycophenolic acid, The serum concentration of Mycophenolic acid can be decreased when it is combined with Levofloxacin.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Levofloxacin.]
[N06AA17, amoxapine, The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Levofloxacin.]
[C07AA12, nadolol, Levofloxacin may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[N04BC04, ropinirole, The risk or severity of adverse effects can be increased when Levofloxacin is combined with Ropinirole.]
[J01CF06, nafcillin, The serum concentration of Levofloxacin can be increased when it is combined with Nafcillin.]
[V03AB15, naloxone, Levofloxacin may decrease the excretion rate of Naloxone which could result in a higher serum level.]
[N06BA01, amphetamine, Amphetamine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[M02AA12, naproxen, Naproxen may increase the neuroexcitatory activities of Levofloxacin.]
[A10BG01, troglitazone, The therapeutic efficacy of Troglitazone can be increased when used in combination with Levofloxacin.]
[N06AX21, duloxetine, Duloxetine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N04BX01, tolcapone, Tolcapone may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[S03AA01, neomycin, Levofloxacin may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[A10BX02, repaglinide, The therapeutic efficacy of Repaglinide can be increased when used in combination with Levofloxacin.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Levofloxacin.]
[B01AC17, tirofiban, Tirofiban may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N05AX14, iloperidone, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Iloperidone.]
[J02AA01, amphotericin B, Amphotericin B may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[S01AA19, ampicillin, The serum concentration of Levofloxacin can be increased when it is combined with Ampicillin.]
[L03AX16, plerixafor, Levofloxacin may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Levofloxacin may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, Levofloxacin may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C01CE01, inamrinone, Levofloxacin may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[C08CA04, nicardipine, The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Levofloxacin.]
[C08CA05, nifedipine, The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Levofloxacin.]
[M02AA17, niflumic acid, Niflumic acid may increase the neuroexcitatory activities of Levofloxacin.]
[C08CA06, nimodipine, The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Levofloxacin.]
[C08CA07, nisoldipine, Nisoldipine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C08CA08, nitrendipine, The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Levofloxacin.]
[R07AX01, nitric oxide, Nitric Oxide may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01XE01, nitrofurantoin, The therapeutic efficacy of Levofloxacin can be decreased when used in combination with Nitrofurantoin.]
[N05CF03, zaleplon, Zaleplon may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N04BC05, pramipexole, Pramipexole may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C02DD01, nitroprusside, Nitroprusside can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Levofloxacin.]
[N06AA10, nortriptyline, The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Levofloxacin.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Levofloxacin.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Ofloxacin.]
[N02AA02, opium, Levofloxacin may decrease the excretion rate of Opium which could result in a higher serum level.]
[G04CA02, tamsulosin, Tamsulosin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01CF04, oxacillin, The serum concentration of Levofloxacin can be increased when it is combined with Oxacillin.]
[V08CB01, ferumoxsil, Ferumoxsil can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N05BA04, oxazepam, Oxazepam may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Levofloxacin.]
[S01BC02, oxyphenbutazone, Oxyphenbutazone may increase the neuroexcitatory activities of Levofloxacin.]
[S01AA04, oxytetracycline, The excretion of Levofloxacin can be decreased when combined with Oxytetracycline.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Levofloxacin.]
[V04CH30, 4-aminohippuric acid, The excretion of Levofloxacin can be decreased when combined with Aminohippuric acid.]
[N05AH05, asenapine, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Asenapine.]
[J04AB30, capreomycin, Levofloxacin may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Levofloxacin.]
[H02AB05, paramethasone, The risk or severity of tendinopathy can be increased when Paramethasone is combined with Levofloxacin.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Levofloxacin.]
[G04BD11, fesoterodine, Levofloxacin may decrease the excretion rate of Fesoterodine which could result in a higher serum level.]
[C07AA23, penbutolol, Levofloxacin may decrease the excretion rate of Penbutolol which could result in a higher serum level.]
[N05AG03, penfluridol, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Penfluridol.]
[S01AA14, penicillin G, The serum concentration of Levofloxacin can be increased when it is combined with Benzylpenicillin.]
[J01CE09, penicillin G procaine, The serum concentration of Levofloxacin can be increased when it is combined with Procaine benzylpenicillin.]
[J01CE02, penicillin V, The serum concentration of Levofloxacin can be increased when it is combined with Phenoxymethylpenicillin.]
[N05CA01, pentobarbital, Pentobarbital may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[L01XX08, pentostatin, Levofloxacin may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, The metabolism of Pentoxifylline can be decreased when combined with Levofloxacin.]
[C08EX02, perhexiline, The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Levofloxacin.]
[N02BE03, phenacetin, The excretion of Levofloxacin can be decreased when combined with Phenacetin.]
[G04BX06, phenazopyridine, Phenazopyridine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N06AF03, phenelzine, Phenelzine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[A10BA01, phenformin, The therapeutic efficacy of Phenformin can be increased when used in combination with Levofloxacin.]
[B01AA02, phenindione, The therapeutic efficacy of Phenindione can be increased when used in combination with Levofloxacin.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Levofloxacin.]
[B01AA04, phenprocoumon, The therapeutic efficacy of Phenprocoumon can be increased when used in combination with Levofloxacin.]
[V03AB36, phentolamine, Phentolamine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[M02AA01, phenylbutazone, Phenylbutazone may increase the neuroexcitatory activities of Levofloxacin.]
[B02BA01, vitamin K1, Phylloquinone may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C08CX01, mibefradil, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Mibefradil.]
[N05AG02, pimozide, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Pimozide.]
[C07AA03, pindolol, Pindolol may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01CA12, piperacillin, The serum concentration of Levofloxacin can be increased when it is combined with Piperacillin.]
[J05AE01, saquinavir, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Saquinavir.]
[N06BX03, piracetam, Levofloxacin may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[S01BC06, piroxicam, Piroxicam may increase the neuroexcitatory activities of Levofloxacin.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Grepafloxacin.]
[J01CA02, pivampicillin, The serum concentration of Levofloxacin can be increased when it is combined with Pivampicillin.]
[A10BG02, rosiglitazone, The therapeutic efficacy of Rosiglitazone can be increased when used in combination with Levofloxacin.]
[C03AA05, polythiazide, Polythiazide may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE03, ritonavir, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Levofloxacin.]
[A10BH03, saxagliptin, The therapeutic efficacy of Saxagliptin can be increased when used in combination with Levofloxacin.]
[B05XA01, potassium chloride, Potassium chloride may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[A10AD04, insulin lispro, The therapeutic efficacy of Insulin lispro can be increased when used in combination with Levofloxacin.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Prajmaline is combined with Levofloxacin.]
[S03BA02, prednisolone, The risk or severity of tendinopathy can be increased when Prednisolone is combined with Levofloxacin.]
[H02AB07, prednisone, The risk or severity of tendinopathy can be increased when Prednisone is combined with Levofloxacin.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Antazoline.]
[C01DX02, prenylamine, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Prenylamine.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Prilocaine.]
[P01BA03, primaquine, The risk or severity of QTc prolongation can be increased when Primaquine is combined with Levofloxacin.]
[M04AB01, probenecid, The serum concentration of Levofloxacin can be increased when it is combined with Probenecid.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Probucol.]
[C01BA02, procainamide, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Procainamide.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Procaine.]
[C10AB05, fenofibrate, Fenofibrate may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N05AB04, prochlorperazine, The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Levofloxacin.]
[N05AA03, promazine, The risk or severity of QTc prolongation can be increased when Promazine is combined with Levofloxacin.]
[R06AD02, promethazine, The risk or severity of QTc prolongation can be increased when Promethazine is combined with Levofloxacin.]
[C01BC03, propafenone, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Propafenone.]
[A03AB05, propantheline, Propantheline may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Romidepsin.]
[N01AX10, propofol, The risk or severity of QTc prolongation can be increased when Propofol is combined with Levofloxacin.]
[C07AA05, propranolol, Propranolol may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N02CC04, rizatriptan, Rizatriptan may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[B01AC09, epoprostenol, Levofloxacin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N06AA11, protriptyline, The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Levofloxacin.]
[N05AX12, aripiprazole, The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Levofloxacin.]
[N07XX07, dalfampridine, Levofloxacin may decrease the excretion rate of Dalfampridine which could result in a higher serum level.]
[P02CC01, pyrantel, Levofloxacin may decrease the excretion rate of Pyrantel which could result in a higher serum level.]
[J04AK01, pyrazinamide, Pyrazinamide may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[R06AC01, pyrilamine, The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Levofloxacin.]
[P01BD01, pyrimethamine, The excretion of Levofloxacin can be decreased when combined with Pyrimethamine.]
[C01BA01, quinidine, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Quinidine.]
[P01BC01, quinine, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Quinine.]
[A02BA02, ranitidine, Ranitidine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C02AA02, reserpine, Reserpine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J05AP01, ribavirin, Ribavirin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[S01XA26, riboflavin, The excretion of Levofloxacin can be decreased when combined with Riboflavin.]
[J04AB02, rifampin, The excretion of Levofloxacin can be decreased when combined with Rifampicin.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Levofloxacin.]
[N02BA05, salicylamide, Salicylamide may increase the neuroexcitatory activities of Levofloxacin.]
[A07EC01, sulfasalazine, Sulfasalazine may increase the neuroexcitatory activities of Levofloxacin.]
[S01BC08, salicylic acid, Salicylic acid may increase the neuroexcitatory activities of Levofloxacin.]
[N05CA06, secobarbital, Secobarbital may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01GB08, sisomicin, Levofloxacin may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Levofloxacin may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[V04CC01, sorbitol, Levofloxacin may decrease the excretion rate of Sorbitol which could result in a higher serum level.]
[C07AA07, sotalol, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Sotalol.]
[C03DA01, spironolactone, Spironolactone may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[S02DA03, antipyrine, Antipyrine may increase the neuroexcitatory activities of Levofloxacin.]
[J01GA01, streptomycin, Levofloxacin may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[A02BX02, sucralfate, Sucralfate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01CG01, sulbactam, Levofloxacin may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01CA16, sulbenicillin, The serum concentration of Levofloxacin can be increased when it is combined with Sulbenicillin.]
[J01EC02, sulfadiazine, The therapeutic efficacy of Sulfadiazine can be increased when used in combination with Levofloxacin.]
[J01EC01, sulfamethoxazole, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Levofloxacin.]
[S01AB02, sulfisoxazole, The therapeutic efficacy of Sulfisoxazole can be increased when used in combination with Levofloxacin.]
[M01AB02, sulindac, Sulindac may increase the neuroexcitatory activities of Levofloxacin.]
[N05AL01, sulpiride, The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Levofloxacin.]
[A10BB04, glibornuride, The therapeutic efficacy of Glibornuride can be increased when used in combination with Levofloxacin.]
[A10BC01, glymidine, The therapeutic efficacy of Glymidine can be increased when used in combination with Levofloxacin.]
[M01AX04, apazone, Azapropazone may increase the neuroexcitatory activities of Levofloxacin.]
[L01BB02, mercaptopurine, The metabolism of Mercaptopurine can be decreased when combined with Levofloxacin.]
[J01CA15, talampicillin, The serum concentration of Levofloxacin can be increased when it is combined with Talampicillin.]
[L02BA01, tamoxifen, The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Levofloxacin.]
[N05CD07, temazepam, Temazepam may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Levofloxacin.]
[B01AE07, dabigatran etexilate, Levofloxacin may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.]
[G03BA03, testosterone, Testosterone may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Tetrabenazine.]
[S01HA03, tetracaine, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Tetracaine.]
[S03AA02, tetracycline, Tetracycline may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N05AE05, lurasidone, The risk or severity of QTc prolongation can be increased when Lurasidone is combined with Levofloxacin.]
[N04BC07, apomorphine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Levofloxacin.]
[R03DA07, theobromine, The metabolism of Theobromine can be decreased when combined with Levofloxacin.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Levofloxacin.]
[P02CA02, thiabendazole, Thiabendazole may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Eribulin is combined with Levofloxacin.]
[R06AD03, thiethylperazine, Thiethylperazine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N05AC02, thioridazine, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Levofloxacin.]
[G04BE06, moxisylyte, Levofloxacin may decrease the excretion rate of Moxisylyte which could result in a higher serum level.]
[B03AB03, sodium ironedetate, Sodium feredetate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N05AL03, tiapride, Levofloxacin may decrease the excretion rate of Tiapride which could result in a higher serum level.]
[J01CA13, ticarcillin, The serum concentration of Levofloxacin can be increased when it is combined with Ticarcillin.]
[B01AC05, ticlopidine, Ticlopidine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[S01ED01, timolol, The risk or severity of QTc prolongation can be increased when Timolol is combined with Levofloxacin.]
[P01AB02, tinidazole, Tinidazole may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[S01AA12, tobramycin, Levofloxacin may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, The therapeutic efficacy of Tolazamide can be increased when used in combination with Levofloxacin.]
[V04CA01, tolbutamide, The therapeutic efficacy of Tolbutamide can be increased when used in combination with Levofloxacin.]
[M02AA21, tolmetin, Tolmetin may increase the neuroexcitatory activities of Levofloxacin.]
[N02AX02, tramadol, Tramadol may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Levofloxacin.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Tretinoin is combined with Levofloxacin.]
[S01BA05, triamcinolone, The risk or severity of tendinopathy can be increased when Triamcinolone is combined with Levofloxacin.]
[C03DB02, triamterene, Triamterene may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD05, triazolam, Triazolam may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C03AA06, trichlormethiazide, Trichlormethiazide may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[A16AX12, trientine, Levofloxacin may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[S01AD02, trifluridine, Trifluridine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[D07AC02, fluclorolone, The risk or severity of tendinopathy can be increased when Fluclorolone is combined with Levofloxacin.]
[R03BA07, mometasone, The risk or severity of tendinopathy can be increased when Mometasone is combined with Levofloxacin.]
[A03AA05, trimebutine, The risk or severity of QTc prolongation can be increased when Trimebutine is combined with Levofloxacin.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Levofloxacin.]
[N03AC02, trimethadione, The risk or severity of QTc prolongation can be increased when Trimethadione is combined with Levofloxacin.]
[J01EA01, trimethoprim, Trimethoprim may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N06AA06, trimipramine, The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Levofloxacin.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Levofloxacin.]
[R03DX07, roflumilast, The serum concentration of Roflumilast can be increased when it is combined with Levofloxacin.]
[L01FX04, ipilimumab, Levofloxacin may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Vandetanib.]
[R02AA14, oxyquinoline, Levofloxacin may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[A10BH05, linagliptin, The therapeutic efficacy of Linagliptin can be increased when used in combination with Levofloxacin.]
[J05AG05, rilpivirine, The risk or severity of QTc prolongation can be increased when Rilpivirine is combined with Levofloxacin.]
[S01AA28, vancomycin, Levofloxacin may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Ezogabine is combined with Levofloxacin.]
[B01AF01, rivaroxaban, Levofloxacin may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Indacaterol is combined with Levofloxacin.]
[C08DA01, verapamil, Verapamil may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N06AX09, viloxazine, Levofloxacin may decrease the excretion rate of Viloxazine which could result in a higher serum level.]
[B03BA01, vitamin B12, Cyanocobalamin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[B01AA03, warfarin, The therapeutic efficacy of Warfarin can be increased when used in combination with Levofloxacin.]
[C03BA10, xipamide, Xipamide may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AF05, zuclopenthixol, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Zuclopenthixol.]
[L01EC01, vemurafenib, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Vemurafenib.]
[M05BA03, pamidronic acid, Pamidronic acid may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[M05BA05, tiludronic acid, Tiludronic acid may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[B06AC02, icatibant, Levofloxacin may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[L01ED01, crizotinib, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Crizotinib.]
[A02BC04, rabeprazole, Rabeprazole may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Levofloxacin.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Ziprasidone.]
[G03AC10, drospirenone, Drospirenone may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AC02, deferiprone, Levofloxacin may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[S01LA01, verteporfin, Levofloxacin may increase the photosensitizing activities of Verteporfin.]
[N02BA01, aspirin, Acetylsalicylic acid may increase the neuroexcitatory activities of Levofloxacin.]
[L01EJ01, ruxolitinib, Levofloxacin may decrease the excretion rate of Ruxolitinib which could result in a higher serum level.]
[G04BD07, tolterodine, The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Levofloxacin.]
[J01DH04, doripenem, Levofloxacin may decrease the excretion rate of Doripenem which could result in a higher serum level.]
[J02AC03, voriconazole, The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Levofloxacin.]
[S01FA01, atropine, The risk or severity of QTc prolongation can be increased when Atropine is combined with Levofloxacin.]
[M01CB03, auranofin, Auranofin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[H02AB11, prednylidene, The risk or severity of tendinopathy can be increased when Prednylidene is combined with Levofloxacin.]
[B03XA04, peginesatide, Levofloxacin may decrease the excretion rate of Peginesatide which could result in a higher serum level.]
[L01BC07, azacitidine, Azacitidine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[L04AX01, azathioprine, Azathioprine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[L01BC05, gemcitabine, Gemcitabine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01CA09, azlocillin, The serum concentration of Levofloxacin can be increased when it is combined with Azlocillin.]
[J01DF01, aztreonam, Aztreonam may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[M03BX01, baclofen, Baclofen may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[A08AA11, lorcaserin, Levofloxacin may decrease the excretion rate of Lorcaserin which could result in a higher serum level.]
[G04BD12, mirabegron, The risk or severity of QTc prolongation can be increased when Mirabegron is combined with Levofloxacin.]
[L02BB04, enzalutamide, Levofloxacin may decrease the excretion rate of Enzalutamide which could result in a higher serum level.]
[A02AA05, magnesium silicate, Magnesium silicate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[H02AA01, aldosterone, The risk or severity of tendinopathy can be increased when Aldosterone is combined with Levofloxacin.]
[D02BA02, octinoxate, Levofloxacin may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[J05AE04, nelfinavir, The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Levofloxacin.]
[N04BD02, rasagiline, Levofloxacin may decrease the excretion rate of Rasagiline which could result in a higher serum level.]
[N02CC03, zolmitriptan, The metabolism of Zolmitriptan can be decreased when combined with Levofloxacin.]
[V09IX04, fluorodeoxyglucose F18, Levofloxacin may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Pasireotide is combined with Levofloxacin.]
[V08CA11, gadofosveset, Levofloxacin may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[A16AX08, teduglutide, Levofloxacin may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Bedaquiline.]
[C04AX11, bencyclane, The risk or severity of QTc prolongation can be increased when Bencyclane is combined with Levofloxacin.]
[A10BH04, alogliptin, The therapeutic efficacy of Alogliptin can be increased when used in combination with Levofloxacin.]
[A16AX09, glycerol phenylbutyrate, Levofloxacin may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.]
[C03AA01, bendroflumethiazide, Bendroflumethiazide may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[L04AX06, pomalidomide, Levofloxacin may decrease the excretion rate of Pomalidomide which could result in a higher serum level.]
[N02BA10, benorilate, Benorilate may increase the neuroexcitatory activities of Levofloxacin.]
[A10BK02, canagliflozin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Levofloxacin.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Gemifloxacin.]
[A12CC09, magnesium orotate, Magnesium orotate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Levofloxacin.]
[A10AE05, insulin detemir, The therapeutic efficacy of Insulin detemir can be increased when used in combination with Levofloxacin.]
[R02AD01, benzocaine, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Benzocaine.]
[A10BX05, pramlintide, The therapeutic efficacy of Pramlintide can be increased when used in combination with Levofloxacin.]
[J02AX04, caspofungin, The excretion of Levofloxacin can be decreased when combined with Caspofungin.]
[L03AA12, ancestim, Levofloxacin may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, Celecoxib may increase the neuroexcitatory activities of Levofloxacin.]
[A12CC05, magnesium aspartate, Magnesium aspartate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N04AC01, benztropine, The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Levofloxacin.]
[L01EC02, dabrafenib, The risk or severity of QTc prolongation can be increased when Dabrafenib is combined with Levofloxacin.]
[R02AX03, benzydamine, Benzydamine may increase the neuroexcitatory activities of Levofloxacin.]
[L01EE01, trametinib, Levofloxacin may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[P03AX06, benzyl alcohol, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Benzyl alcohol.]
[V09AX05, florbetapir F-18, Levofloxacin may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[B03AB04, ferric hydroxide, Ferric hydroxide can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N06AX28, levomilnacipran, Levofloxacin may decrease the excretion rate of Levomilnacipran which could result in a higher serum level.]
[J05AJ03, dolutegravir, The excretion of Levofloxacin can be decreased when combined with Dolutegravir.]
[C08EA02, bepridil, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Bepridil.]
[A10BJ03, lixisenatide, The therapeutic efficacy of Lixisenatide can be increased when used in combination with Levofloxacin.]
[C02KX04, macitentan, Levofloxacin may decrease the excretion rate of Macitentan which could result in a higher serum level.]
[N06AX26, vortioxetine, Levofloxacin may decrease the excretion rate of Vortioxetine which could result in a higher serum level.]
[G03AC08, etonogestrel, Etonogestrel may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[V03AE05, sucroferric oxyhydroxide, Iron sucrose can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J05AP08, sofosbuvir, Levofloxacin may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[A10BK01, dapagliflozin, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Levofloxacin.]
[C01CA27, droxidopa, Levofloxacin may decrease the excretion rate of Droxidopa which could result in a higher serum level.]
[N05CH03, tasimelteon, Levofloxacin may decrease the excretion rate of Tasimelteon which could result in a higher serum level.]
[L04AA32, apremilast, Levofloxacin may decrease the excretion rate of Apremilast which could result in a higher serum level.]
[L02BG02, formestane, Levofloxacin may decrease the excretion rate of Formestane which could result in a higher serum level.]
[S03BA03, betamethasone, The risk or severity of tendinopathy can be increased when Betamethasone is combined with Levofloxacin.]
[V03AB34, fomepizole, Levofloxacin may decrease the excretion rate of Fomepizole which could result in a higher serum level.]
[A10BJ04, albiglutide, The therapeutic efficacy of Albiglutide can be increased when used in combination with Levofloxacin.]
[L01ED02, ceritinib, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Ceritinib.]
[A03BA03, hyoscyamine, The risk or severity of QTc prolongation can be increased when Hyoscyamine is combined with Levofloxacin.]
[B01AA07, acenocoumarol, The therapeutic efficacy of Acenocoumarol can be increased when used in combination with Levofloxacin.]
[N07XX08, tafamidis, The excretion of Levofloxacin can be decreased when combined with Tafamidis.]
[A10BK03, empagliflozin, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Levofloxacin.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Olodaterol is combined with Levofloxacin.]
[V08AA01, diatrizoic acid, Diatrizoate may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[V08AA04, iothalamic acid, Diatrizoate may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[A16AX10, eliglustat, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Eliglustat.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[A10BJ05, dulaglutide, The therapeutic efficacy of Dulaglutide can be increased when used in combination with Levofloxacin.]
[V03AE08, ferric citrate, Tetraferric tricitrate decahydrate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S03AA06, gentamicin, Levofloxacin may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[B01AA01, dicumarol, The therapeutic efficacy of Dicoumarol can be increased when used in combination with Levofloxacin.]
[B01AF03, edoxaban, Levofloxacin may decrease the excretion rate of Edoxaban which could result in a higher serum level.]
[N06AX11, mirtazapine, The risk or severity of QTc prolongation can be increased when Mirtazapine is combined with Levofloxacin.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Lenvatinib.]
[L01XH03, panobinostat, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Panobinostat.]
[N02BE01, acetaminophen, Acetaminophen may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[L01DC01, bleomycin, Bleomycin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[B01AA11, tioclomarol, The therapeutic efficacy of Tioclomarol can be increased when used in combination with Levofloxacin.]
[C01EB17, ivabradine, Ivabradine may increase the QTc-prolonging activities of Levofloxacin.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[A06AD03, magnesium peroxide, Magnesium peroxide can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A10BF01, acarbose, The therapeutic efficacy of Acarbose can be increased when used in combination with Levofloxacin.]
[M02AA25, aceclofenac, Aceclofenac may increase the neuroexcitatory activities of Levofloxacin.]
[M01AB11, acemetacin, Acemetacin may increase the neuroexcitatory activities of Levofloxacin.]
[S01EC01, acetazolamide, Acetazolamide may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AE06, insulin degludec, The therapeutic efficacy of Insulin degludec can be increased when used in combination with Levofloxacin.]
[V03AB37, idarucizumab, Levofloxacin may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Levofloxacin.]
[L01XG03, ixazomib, Levofloxacin may decrease the excretion rate of Ixazomib which could result in a higher serum level.]
[A10BB31, acetohexamide, The therapeutic efficacy of Acetohexamide can be increased when used in combination with Levofloxacin.]
[G04CA01, alfuzosin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Levofloxacin.]
[M04AB05, lesinurad, Levofloxacin may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[M01AE16, alminoprofen, Alminoprofen may increase the neuroexcitatory activities of Levofloxacin.]
[N03AX23, brivaracetam, Levofloxacin may decrease the excretion rate of Brivaracetam which could result in a higher serum level.]
[N05BA08, bromazepam, Levofloxacin may decrease the excretion rate of Bromazepam which could result in a higher serum level.]
[N04BC01, bromocriptine, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Levofloxacin.]
[A02AD05, aluminum magnesium silicate, Almasilate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02AB03, aluminum phosphate, Aluminium phosphate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Levofloxacin.]
[C03CA02, bumetanide, Bumetanide may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB01, bupivacaine, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Bupivacaine.]
[C07AA19, bupranolol, The risk or severity of QTc prolongation can be increased when Bupranolol is combined with Levofloxacin.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Buserelin is combined with Levofloxacin.]
[N05BE01, buspirone, Buspirone may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Arsenic trioxide.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Artemether.]
[M02AA03, clofezone, Rabeprazole may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Levofloxacin.]
[J01CE04, azidocillin, The serum concentration of Levofloxacin can be increased when it is combined with Azidocillin.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Levofloxacin.]
[J01CA06, bacampicillin, The serum concentration of Levofloxacin can be increased when it is combined with Bacampicillin.]
[L01EF02, ribociclib, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Ribociclib.]
[A07EC04, balsalazide, Balsalazide may increase the neuroexcitatory activities of Levofloxacin.]
[R03DA08, bamifylline, The metabolism of Bamifylline can be decreased when combined with Levofloxacin.]
[A06AH05, naldemedine, Levofloxacin may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Levofloxacin.]
[N06BC01, caffeine, The metabolism of Caffeine can be decreased when combined with Levofloxacin.]
[A10BX06, benfluorex, The therapeutic efficacy of Benfluorex can be increased when used in combination with Levofloxacin.]
[S01HA02, benoxinate, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Oxybuprocaine.]
[P01CA02, benznidazole, Levofloxacin may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[J01XX08, linezolid, The excretion of Levofloxacin can be decreased when combined with Linezolid.]
[J05AF06, abacavir, Abacavir may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N07XX13, valbenazine, Levofloxacin may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[L01ED04, brigatinib, The excretion of Levofloxacin can be decreased when combined with Brigatinib.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Delafloxacin is combined with Levofloxacin.]
[L01BC06, capecitabine, Capecitabine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[L01XX59, enasidenib, The excretion of Levofloxacin can be decreased when combined with Enasidenib.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Vorinostat is combined with Levofloxacin.]
[L01EF03, abemaciclib, The excretion of Abemaciclib can be decreased when combined with Levofloxacin.]
[C07AB07, bisoprolol, Bisoprolol may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J05AG03, efavirenz, The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Levofloxacin.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, The risk or severity of tendinopathy can be increased when Budesonide is combined with Levofloxacin.]
[M01AB07, bumadizone, Bumadizone may increase the neuroexcitatory activities of Levofloxacin.]
[N06AA15, butriptyline, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Butriptyline.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Acetyldigoxin is combined with Levofloxacin.]
[A10BJ06, semaglutide, The therapeutic efficacy of Semaglutide can be increased when used in combination with Levofloxacin.]
[N01BX04, capsaicin, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Capsaicin.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Ertugliflozin can be increased when used in combination with Levofloxacin.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Acrivastine is combined with Levofloxacin.]
[C09AA01, captopril, The excretion of Levofloxacin can be decreased when combined with Captopril.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Macimorelin.]
[L02BB05, apalutamide, Levofloxacin may decrease the excretion rate of Apalutamide which could result in a higher serum level.]
[N03AF01, carbamazepine, Levofloxacin may decrease the excretion rate of Carbamazepine which could result in a higher serum level.]
[J01CA03, carbenicillin, The serum concentration of Levofloxacin can be increased when it is combined with Carbenicillin.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Levofloxacin.]
[L04AA37, baricitinib, Levofloxacin may decrease the excretion rate of Baricitinib which could result in a higher serum level.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Encorafenib.]
[J01DD14, ceftibuten, Ceftibuten may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01GB14, plazomicin, Levofloxacin may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[C07AB08, celiprolol, The risk or severity of QTc prolongation can be increased when Celiprolol is combined with Levofloxacin.]
[L01XX62, ivosidenib, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Ivosidenib.]
[P01BA07, tafenoquine, The excretion of Levofloxacin can be decreased when combined with Tafenoquine.]
[A16AX14, migalastat, Levofloxacin may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, Levofloxacin may decrease the excretion rate of Stiripentol which could result in a higher serum level.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Levofloxacin.]
[A10BB06, carbutamide, The therapeutic efficacy of Carbutamide can be increased when used in combination with Levofloxacin.]
[N01BA04, chloroprocaine, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Chloroprocaine.]
[D08AE05, chloroxylenol, Levofloxacin may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[M01AC05, lornoxicam, Lornoxicam may increase the neuroexcitatory activities of Levofloxacin.]
[R03DA02, oxtriphylline, The metabolism of Oxtriphylline can be decreased when combined with Levofloxacin.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Inotersen is combined with Levofloxacin.]
[L01AD01, carmustine, Carmustine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[L01EX13, gilteritinib, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Gilteritinib.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Amifampridine.]
[A06AX05, prucalopride, Levofloxacin may decrease the excretion rate of Prucalopride which could result in a higher serum level.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Cibenzoline is combined with Levofloxacin.]
[B01AC23, cilostazol, The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Levofloxacin.]
[P02BX04, triclabendazole, The risk or severity of QTc prolongation can be increased when Triclabendazole is combined with Levofloxacin.]
[J01FA09, clarithromycin, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Clarithromycin.]
[N06BA14, solriamfetol, Levofloxacin may decrease the excretion rate of Solriamfetol which could result in a higher serum level.]
[N05BA09, clobazam, Clobazam may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[H02AB14, cloprednol, The risk or severity of tendinopathy can be increased when Cloprednol is combined with Levofloxacin.]
[V03AE07, calcium acetate, Calcium acetate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A12CC06, magnesium lactate, Magnesium lactate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V03AE02, sevelamer, Sevelamer can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[H02AB17, cortivazol, The risk or severity of tendinopathy can be increased when Cortivazol is combined with Levofloxacin.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01CF03, methicillin, The serum concentration of Levofloxacin can be increased when it is combined with Meticillin.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[L01EX15, pexidartinib, The excretion of Levofloxacin can be decreased when combined with Pexidartinib.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C03BX03, cicletanine, Cicletanine may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[L01EJ02, fedratinib, The excretion of Levofloxacin can be decreased when combined with Fedratinib.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Entrectinib.]
[N07XX11, pitolisant, Levofloxacin may increase the QTc-prolonging activities of Pitolisant.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Levofloxacin.]
[N04CX01, istradefylline, The excretion of Levofloxacin can be decreased when combined with Istradefylline.]
[C03AA09, cyclothiazide, Cyclothiazide may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AE03, insulin, regular, pork, The therapeutic efficacy of Insulin pork can be increased when used in combination with Levofloxacin.]
[J01XX09, daptomycin, Daptomycin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01DB01, cephalexin, Cephalexin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01DB09, cephradine, Cefradine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[H02AB13, deflazacort, The risk or severity of tendinopathy can be increased when Deflazacort is combined with Levofloxacin.]
[A16AX16, givosiran, Givosiran may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[M09AX08, golodirsen, Levofloxacin may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Levofloxacin.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Dexchlorpheniramine.]
[S01XA12, dexpanthenol, Levofloxacin may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[L01XX72, tazemetostat, The excretion of Levofloxacin can be decreased when combined with Tazemetostat.]
[J05AB16, remdesivir, The excretion of Levofloxacin can be decreased when combined with Remdesivir.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Levofloxacin.]
[R02AA03, dichlorobenzyl alcohol, Levofloxacin may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, Levofloxacin may decrease the excretion rate of Dienogest which could result in a higher serum level.]
[L01XD01, porfimer sodium, Levofloxacin may increase the photosensitizing activities of Porfimer sodium.]
[M01AH02, rofecoxib, Rofecoxib may increase the neuroexcitatory activities of Levofloxacin.]
[C08CA16, clevidipine, Levofloxacin may decrease the excretion rate of Clevidipine which could result in a higher serum level.]
[C01BD07, dronedarone, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Dronedarone.]
[V03AE03, lanthanum carbonate, Lanthanum carbonate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S03AA08, chloramphenicol, The excretion of Levofloxacin can be decreased when combined with Chloramphenicol.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Chlorcyclizine is combined with Levofloxacin.]
[L01EH03, tucatinib, The excretion of Levofloxacin can be decreased when combined with Tucatinib.]
[L01EX17, capmatinib, The excretion of Levofloxacin can be decreased when combined with Capmatinib.]
[D07XB03, fluprednidene, The risk or severity of tendinopathy can be increased when Fluprednidene is combined with Levofloxacin.]
[M01AC04, droxicam, Droxicam may increase the neuroexcitatory activities of Levofloxacin.]
[L01EX19, ripretinib, The excretion of Levofloxacin can be decreased when combined with Ripretinib.]
[V08CA05, mangafodipir, Levofloxacin may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[L01EX22, selpercatinib, The excretion of Levofloxacin can be decreased when combined with Selpercatinib.]
[M02AA27, dexketoprofen, Dexketoprofen may increase the neuroexcitatory activities of Levofloxacin.]
[R02AD04, dyclonine, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Dyclonine.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Ebastine is combined with Levofloxacin.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Fostemsavir is combined with Levofloxacin.]
[M09AX10, risdiplam, The serum concentration of Levofloxacin can be increased when it is combined with Risdiplam.]
[P01BA01, chloroquine, The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Levofloxacin.]
[L01EX23, pralsetinib, The excretion of Levofloxacin can be decreased when combined with Pralsetinib.]
[C03AA04, chlorothiazide, Chlorothiazide may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[R06AB04, chlorpheniramine, The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with Levofloxacin.]
[N05AA01, chlorpromazine, The risk or severity of QTc prolongation can be increased when Chlorpromazine is combined with Levofloxacin.]
[A10BB02, chlorpropamide, The therapeutic efficacy of Chlorpropamide can be increased when used in combination with Levofloxacin.]
[N05AF03, chlorprothixene, The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Levofloxacin.]
[C03BA04, chlorthalidone, Chlorthalidone may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BB03, chlorzoxazone, Chlorzoxazone may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N02BA07, ethenzamide, Ethenzamide may increase the neuroexcitatory activities of Levofloxacin.]
[N02BA03, choline salicylate, Levofloxacin may decrease the excretion rate of Choline salicylate which could result in a higher serum level.]
[M01AB08, etodolac, Etodolac may increase the neuroexcitatory activities of Levofloxacin.]
[M02AA06, etofenamate, Etofenamate may increase the neuroexcitatory activities of Levofloxacin.]
[B06AC06, berotralstat, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Berotralstat.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Relugolix is combined with Levofloxacin.]
[M01AX25, chondroitin sulfates, Levofloxacin may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[J05AJ04, cabotegravir, The excretion of Levofloxacin can be decreased when combined with Cabotegravir.]
[V03AF12, trilaciclib, The excretion of Levofloxacin can be decreased when combined with Trilaciclib.]
[N03AX10, felbamate, The risk or severity of QTc prolongation can be increased when Felbamate is combined with Levofloxacin.]
[M01AE05, fenbufen, Fenbufen may increase the neuroexcitatory activities of Levofloxacin.]
[N06BA10, fenethylline, The metabolism of Fenethylline can be decreased when combined with Levofloxacin.]
[C01CA19, fenoldopam, Fenoldopam may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[V08CA07, ferric ammonium citrate, Ferric ammonium citrate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V03AB31, prussian blue insoluble, Prussian blue can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AB02, iron sucrose, Iron sucrose can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA05, ferrous chloride, Ferrous chloride can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA02, ferrous fumarate, Ferrous fumarate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA03, ferrous gluconate, Ferrous gluconate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA06, ferrous succinate, Ferrous succinate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B03AA07, ferrous sulfate, Ferrous sulfate anhydrous can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01DD15, cefdinir, Cefdinir may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Flumequine is combined with Levofloxacin.]
[R03BA03, flunisolide, The risk or severity of tendinopathy can be increased when Flunisolide is combined with Levofloxacin.]
[S02BA08, fluocinolone acetonide, The risk or severity of tendinopathy can be increased when Fluocinolone acetonide is combined with Levofloxacin.]
[S01JA01, fluorescein, The excretion of Levofloxacin can be decreased when combined with Fluorescein.]
[N02BG07, flupirtine, Levofloxacin may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Levofloxacin.]
[A10AF01, insulin, regular, human, The therapeutic efficacy of Insulin human can be increased when used in combination with Levofloxacin.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Levofloxacin.]
[B03AB10, ferric maltol, Ferric maltol can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A02BA01, cimetidine, The serum concentration of Levofloxacin can be increased when it is combined with Cimetidine.]
[V08CA04, gadoteridol, Gadoteridol may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N07CA02, cinnarizine, The risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Levofloxacin.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Levofloxacin.]
[S03AA07, ciprofloxacin, The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Levofloxacin.]
[L01XA01, cisplatin, Levofloxacin may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06AB04, citalopram, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Citalopram.]
[C03DA05, finerenone, Finerenone may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Levofloxacin is combined with Fexinidazole.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Mobocertinib.]
[V09AB03, ioflupane I-123, Levofloxacin may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Levofloxacin may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Levofloxacin may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Clemastine.]
[M01AG01, mefenamic acid, Mefenamic acid may increase the neuroexcitatory activities of Levofloxacin.]
[A10BB12, glimepiride, The therapeutic efficacy of Glimepiride can be increased when used in combination with Levofloxacin.]
[A10BB08, gliquidone, The therapeutic efficacy of Gliquidone can be increased when used in combination with Levofloxacin.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Levofloxacin.]
[N01BB10, levobupivacaine, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Levobupivacaine.]
[L01EJ03, pacritinib, The risk or severity of QTc prolongation can be increased when Pacritinib is combined with Levofloxacin.]
[N06AA04, clomipramine, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Clomipramine.]
[N03AE01, clonazepam, Clonazepam may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J05AH02, oseltamivir, Oseltamivir may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[A10BX16, tirzepatide, The therapeutic efficacy of Tirzepatide can be increased when used in combination with Levofloxacin.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[A04AA01, ondansetron, The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Levofloxacin.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Granisetron is combined with Levofloxacin.]
[J01CF02, cloxacillin, The serum concentration of Levofloxacin can be increased when it is combined with Cloxacillin.]
[N05AH02, clozapine, The risk or severity of QTc prolongation can be increased when Clozapine is combined with Levofloxacin.]
[A10BX01, guar gum, The therapeutic efficacy of Guar gum can be increased when used in combination with Levofloxacin.]
[A10BK06, sotagliflozin, The therapeutic efficacy of Sotagliflozin can be increased when used in combination with Levofloxacin.]
[J01GB12, arbekacin, Levofloxacin may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[S02DA02, cocaine, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Cocaine.]
[M01AX13, proquazone, Proquazone may increase the neuroexcitatory activities of Levofloxacin.]
[R05DA04, codeine, The excretion of Levofloxacin can be decreased when combined with Codeine.]
[J01CA18, hetacillin, The serum concentration of Levofloxacin can be increased when it is combined with Hetacillin.]
[M04AC01, colchicine, Levofloxacin may decrease the excretion rate of Colchicine which could result in a higher serum level.]
[J01XB01, colistin, Levofloxacin may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[A02AD04, hydrotalcite, Hydrotalcite can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Desflurane is combined with Levofloxacin.]
[A04AA03, tropisetron, Levofloxacin may decrease the excretion rate of Tropisetron which could result in a higher serum level.]
[A10BX03, nateglinide, The therapeutic efficacy of Nateglinide can be increased when used in combination with Levofloxacin.]
[N02BA16, imidazole-2-hydroxybenzoate, Imidazole salicylate may increase the neuroexcitatory activities of Levofloxacin.]
[H01AC03, mecasermin, The therapeutic efficacy of Mecasermin can be increased when used in combination with Levofloxacin.]
[A10AE04, insulin glargine, The therapeutic efficacy of Insulin glargine can be increased when used in combination with Levofloxacin.]
[J01FA15, telithromycin, The risk or severity of QTc prolongation can be increased when Telithromycin is combined with Levofloxacin.]
[R03BA08, ciclesonide, The risk or severity of tendinopathy can be increased when Ciclesonide is combined with Levofloxacin.]
[B01AC10, indobufen, Indobufen may increase the neuroexcitatory activities of Levofloxacin.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Levofloxacin.]
[J05AB14, valganciclovir, Levofloxacin may decrease the excretion rate of Valganciclovir which could result in a higher serum level.]
[J05AF09, emtricitabine, The excretion of Levofloxacin can be decreased when combined with Emtricitabine.]
[C05BB03, invert sugar, Levofloxacin may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Levofloxacin may decrease the excretion rate of Iodixanol which could result in a higher serum level.]
[V08AB05, iopromide, Levofloxacin may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Levofloxacin may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Levofloxacin may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, Valdecoxib may increase the neuroexcitatory activities of Levofloxacin.]
[N02CC05, almotriptan, Almotriptan may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[M01AH04, parecoxib, Parecoxib may increase the neuroexcitatory activities of Levofloxacin.]
[J02AC02, itraconazole, The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Levofloxacin.]
[S01AD03, acyclovir, Acyclovir may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Emedastine is combined with Levofloxacin.]
[N05BA10, ketazolam, Levofloxacin may decrease the excretion rate of Ketazolam which could result in a higher serum level.]
[M01AA06, kebuzone, Kebuzone may increase the neuroexcitatory activities of Levofloxacin.]
[L01EA01, imatinib, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Imatinib.]
[J02AC04, posaconazole, The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Levofloxacin.]
[C08CA09, lacidipine, The risk or severity of QTc prolongation can be increased when Lacidipine is combined with Levofloxacin.]
[N03AX09, lamotrigine, The risk or severity of QTc prolongation can be increased when Lamotrigine is combined with Levofloxacin.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Levofloxacin.]
[S01BA03, cortisone, The risk or severity of tendinopathy can be increased when Cortisone is combined with Levofloxacin.]
[N07BC04, lofexidine, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Lofexidine.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Levofloxacin.]
[M01AB09, lonazolac, Lonazolac may increase the neuroexcitatory activities of Levofloxacin.]
[M02AA31, loxoprofen, Loxoprofen may increase the neuroexcitatory activities of Levofloxacin.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C09AA03, lisinopril, Lisinopril may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[A02AD02, magaldrate, Magaldrate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A06AD01, magnesium carbonate, Magnesium carbonate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[H02AB15, meprednisone, The risk or severity of tendinopathy can be increased when Meprednisone is combined with Levofloxacin.]
[R06AD07, mequitazine, The risk or severity of QTc prolongation can be increased when Mequitazine is combined with Levofloxacin.]
[J01DH02, meropenem, Meropenem may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Adenosine is combined with Levofloxacin.]
[J01CA14, methampicillin, The serum concentration of Levofloxacin can be increased when it is combined with Metampicillin.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Levofloxacin.]
[C03DA04, eplerenone, Eplerenone may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD03, metylperon, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Melperone.]
[C03AA07, cyclopenthiazide, Cyclopenthiazide may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[A10BF02, miglitol, The therapeutic efficacy of Miglitol can be increased when used in combination with Levofloxacin.]
[J05AF07, tenofovir disoproxil, Tenofovir disoproxil may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[S01XA18, cyclosporine, The serum concentration of Cyclosporine can be increased when it is combined with Levofloxacin.]
[R06AX02, cyproheptadine, The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Levofloxacin.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Levofloxacin.]
[M02AA02, mofebutazone, Mofebutazone may increase the neuroexcitatory activities of Levofloxacin.]
[M01AX22, morniflumate, Morniflumate may increase the neuroexcitatory activities of Levofloxacin.]
[C03XA02, conivaptan, Conivaptan may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE09, vardenafil, The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Levofloxacin.]
[M01AH05, etoricoxib, Etoricoxib may increase the neuroexcitatory activities of Levofloxacin.]
[L01AX04, dacarbazine, Dacarbazine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[M01AX01, nabumetone, Nabumetone may increase the neuroexcitatory activities of Levofloxacin.]
[N07BB05, nalmefene, Levofloxacin may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[S01GX04, nedocromil, Nedocromil may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N06AX06, nefazodone, Levofloxacin may decrease the excretion rate of Nefazodone which could result in a higher serum level.]
[C01DX16, nicorandil, Levofloxacin may decrease the excretion rate of Nicorandil which could result in a higher serum level.]
[L02BB02, nilutamide, Nilutamide may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C01CA23, theodrenaline, The metabolism of Theodrenaline can be decreased when combined with Levofloxacin.]
[M03AC11, cisatracurium, Levofloxacin may increase the neuromuscular blocking activities of Cisatracurium.]
[B01AX05, fondaparinux, Fondaparinux may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N06AB10, escitalopram, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Escitalopram.]
[G04BD08, solifenacin, The risk or severity of QTc prolongation can be increased when Solifenacin is combined with Levofloxacin.]
[A07EC03, olsalazine, Olsalazine may increase the neuroexcitatory activities of Levofloxacin.]
[N06AA01, desipramine, The risk or severity of QTc prolongation can be increased when Desipramine is combined with Levofloxacin.]
[H01BA02, desmopressin, Desmopressin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[D07XC02, desoximetasone, The risk or severity of tendinopathy can be increased when Desoximetasone is combined with Levofloxacin.]
[V04CH02, indigo carmine, Levofloxacin may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[H02AA03, desoxycorticosterone, The risk or severity of tendinopathy can be increased when Desoxycortone is combined with Levofloxacin.]
[J01DH03, ertapenem, Ertapenem may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Levofloxacin.]
[M01AE12, oxaprozin, Oxaprozin may increase the neuroexcitatory activities of Levofloxacin.]
[S03BA01, dexamethasone, The risk or severity of tendinopathy can be increased when Dexamethasone is combined with Levofloxacin.]
[N06BA02, dextroamphetamine, Amphetamine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C01DA05, pentaerythritol tetranitrate, Levofloxacin may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[C04AD01, pentifylline, The metabolism of Pentifylline can be decreased when combined with Levofloxacin.]
[P03AC04, permethrin, Levofloxacin may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, Diazepam may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01CE05, phenethicillin, The serum concentration of Levofloxacin can be increased when it is combined with Pheneticillin.]
[R02AA19, phenol, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Phenol.]
[S02DA04, dibucaine, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Cinchocaine.]
[R05DA08, pholcodine, Levofloxacin may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[S01EC02, dichlorphenamide, Diclofenamide may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC03, diclofenac, Diclofenac may increase the neuroexcitatory activities of Levofloxacin.]
[J01CF01, dicloxacillin, The serum concentration of Levofloxacin can be increased when it is combined with Dicloxacillin.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Levofloxacin.]
[A03AA07, dicyclomine, Dicyclomine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J05AF02, didanosine, Didanosine can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A03AX04, pinaverium, The risk or severity of QTc prolongation can be increased when Pinaverium is combined with Levofloxacin.]
[A10BG03, pioglitazone, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Levofloxacin.]
[L01EB02, erlotinib, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Erlotinib.]
[C03CA03, piretanide, Piretanide may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[C08CA03, isradipine, The risk or severity of QTc prolongation can be increased when Isradipine is combined with Levofloxacin.]
[D07XC04, diflucortolone, The risk or severity of tendinopathy can be increased when Difluocortolone is combined with Levofloxacin.]
[N02BA11, diflunisal, Diflunisal may increase the neuroexcitatory activities of Levofloxacin.]
[C01AA04, digitoxin, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Levofloxacin.]
[C01AA05, digoxin, Levofloxacin may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[N02AA03, hydromorphone, Hydromorphone may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[L04AX04, lenalidomide, Lenalidomide may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J05AE08, atazanavir, The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Levofloxacin.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Levofloxacin.]
[H03BC01, potassium perchlorate, Levofloxacin may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.]
[V03AB04, pralidoxime, Pralidoxime may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[D04AB07, pramoxine, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Pramocaine.]
[C08DB01, diltiazem, The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Levofloxacin.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Levofloxacin.]
[V03AB09, dimercaprol, Levofloxacin may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[M02AX03, dimethyl sulfoxide, Dimethyl sulfoxide may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N06BC02, propentofylline, The metabolism of Propentofylline can be decreased when combined with Levofloxacin.]
[J01CE03, propicillin, The serum concentration of Levofloxacin can be increased when it is combined with Propicillin.]
[N02BB04, propyphenazone, Propyphenazone may increase the neuroexcitatory activities of Levofloxacin.]
[M01AB14, proglumetacin, Proglumetacin may increase the neuroexcitatory activities of Levofloxacin.]
[G02AD02, dinoprostone, The excretion of Levofloxacin can be decreased when combined with Dinoprostone.]
[S01HA04, proparacaine, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Proparacaine.]
[R03DA03, proxyphylline, The metabolism of Proxyphylline can be decreased when combined with Levofloxacin.]
[R06AA02, diphenhydramine, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Diphenhydramine.]
[C09AA06, quinapril, Quinapril can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A03FA02, cisapride, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Cisapride.]
[S01AX06, resorcinol, Levofloxacin may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Disopyramide.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Levofloxacin.]
[S02AA12, rifamycin SV, The excretion of Levofloxacin can be decreased when combined with Rifamycin.]
[N05AX08, risperidone, The risk or severity of QTc prolongation can be increased when Risperidone is combined with Levofloxacin.]
[R06AE09, levocetirizine, The risk or severity of QTc prolongation can be increased when Levocetirizine is combined with Levofloxacin.]
[N01BB09, ropivacaine, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Ropivacaine.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Levofloxacin.]
[L01EX01, sunitinib, The therapeutic efficacy of Sunitinib can be increased when used in combination with Levofloxacin.]
[C03XA01, tolvaptan, Tolvaptan may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XG01, bortezomib, The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Levofloxacin.]
[G04BE08, tadalafil, Tadalafil may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[S01BC05, ketorolac, Ketorolac may increase the neuroexcitatory activities of Levofloxacin.]
[C01EB18, ranolazine, The risk or severity of QTc prolongation can be increased when Ranolazine is combined with Levofloxacin.]
[N02BA06, salsalate, Salsalate may increase the neuroexcitatory activities of Levofloxacin.]
[R03AC12, salmeterol, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Levofloxacin.]
[H05BA01, salmon calcitonin, Salmon calcitonin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C01CA07, dobutamine, Dobutamine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Domperidone.]
[C01CA04, dopamine, Dopamine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N06AA16, dothiepin, The risk or severity of QTc prolongation can be increased when Dosulepin is combined with Levofloxacin.]
[N06AA12, doxepin, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Levofloxacin.]
[J01AA02, doxycycline, Doxycycline may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[R06AA09, doxylamine, The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Levofloxacin.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Levofloxacin.]
[N05AD08, droperidol, The risk or severity of QTc prolongation can be increased when Droperidol is combined with Levofloxacin.]
[A08AA10, sibutramine, Sibutramine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[A12CA02, sodium sulfate, Levofloxacin may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[R03DA01, dyphylline, The metabolism of Dyphylline can be decreased when combined with Levofloxacin.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Sultopride.]
[N02CC01, sumatriptan, Sumatriptan may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[V04CX07, edrophonium, Edrophonium may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C07AB13, talinolol, The risk or severity of QTc prolongation can be increased when Talinolol is combined with Levofloxacin.]
[H01AA01, corticotropin, The risk or severity of tendinopathy can be increased when Corticotropin is combined with Levofloxacin.]
[J01CG02, tazobactam, The excretion of Levofloxacin can be decreased when combined with Tazobactam.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Temafloxacin.]
[J01CA17, temocillin, The serum concentration of Levofloxacin can be increased when it is combined with Temocillin.]
[L01AX03, temozolomide, Temozolomide may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[M01AC02, tenoxicam, Tenoxicam may increase the neuroexcitatory activities of Levofloxacin.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Terodiline.]
[C09AA02, enalapril, The excretion of Levofloxacin can be decreased when combined with Enalapril.]
[M01AG02, tolfenamic acid, Tolfenamic acid may increase the neuroexcitatory activities of Levofloxacin.]
[N06AG03, toloxatone, Levofloxacin may decrease the excretion rate of Toloxatone which could result in a higher serum level.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Levofloxacin.]
[N03AX11, topiramate, Topiramate may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Toremifene.]
[C03CA04, torsemide, Torasemide may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CC01, chloral hydrate, Levofloxacin may decrease the excretion rate of Chloral hydrate which could result in a higher serum level.]
[H02CA01, trilostane, The risk or severity of tendinopathy can be increased when Trilostane is combined with Levofloxacin.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Triptorelin is combined with Levofloxacin.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Levofloxacin.]
[S01GX10, epinastine, The risk or severity of QTc prolongation can be increased when Epinastine is combined with Levofloxacin.]
[N06AX16, venlafaxine, Venlafaxine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[B05XA12, zinc chloride, Zinc chloride can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[B05XA18, zinc sulfate, Zinc sulfate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[M01AB04, zomepirac, Zomepirac may increase the neuroexcitatory activities of Levofloxacin.]
[N03AX15, zonisamide, Zonisamide may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[A10AB06, insulin glulisine, human, The therapeutic efficacy of Insulin glulisine can be increased when used in combination with Levofloxacin.]
[L01XA02, carboplatin, Carboplatin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C02AC02, guanfacine, Guanfacine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C01BG01, moricizine, The risk or severity of QTc prolongation can be increased when Moricizine is combined with Levofloxacin.]
[N03AG01, valproic acid, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Valproic acid.]
[L03AX05, pidotimod, Levofloxacin may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[S01AA17, erythromycin, The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Levofloxacin.]
[N05CD04, estazolam, Levofloxacin may decrease the excretion rate of Estazolam which could result in a higher serum level.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[G03CA03, estradiol, Estradiol may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J04AK02, ethambutol, Ethambutol may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[R03BA09, fluticasone furoate, The risk or severity of tendinopathy can be increased when Fluticasone furoate is combined with Levofloxacin.]
[R03BA05, fluticasone, The risk or severity of tendinopathy can be increased when Fluticasone is combined with Levofloxacin.]
[V08CA03, gadodiamide, Gadodiamide may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Ibutilide.]
[N03AD01, ethosuximide, The risk or severity of QTc prolongation can be increased when Ethosuximide is combined with Levofloxacin.]
[N01BX01, ethyl chloride, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Ethyl chloride.]
[M01AC06, meloxicam, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Meloxicam.]
[N01BB07, etidocaine, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Etidocaine.]
[N01AX07, etomidate, Etomidate may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Levofloxacin.]
[L04AD02, tacrolimus, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Levofloxacin.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Fleroxacin is combined with Levofloxacin.]
[R06AX11, astemizole, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Astemizole.]
[R06AX12, terfenadine, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Terfenadine.]
[P01AX07, trimetrexate, Levofloxacin may decrease the excretion rate of Trimetrexate which could result in a higher serum level.]
[N06AX12, bupropion, Levofloxacin may decrease the excretion rate of Bupropion which could result in a higher serum level.]
[N06AB08, fluvoxamine, Fluvoxamine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Encainide is combined with Levofloxacin.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Levofloxacin.]
[C10AA03, pravastatin, The excretion of Levofloxacin can be decreased when combined with Pravastatin.]
[M01CB01, gold sodium thiomalate, Levofloxacin may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, Levofloxacin may decrease the excretion rate of Dextran which could result in a higher serum level.]
[V03AF02, dexrazoxane, Dexrazoxane may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Levofloxacin.]
[A16AA01, levocarnitine, Levocarnitine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C08CA02, felodipine, The risk or severity of QTc prolongation can be increased when Felodipine is combined with Levofloxacin.]
[C08EA01, fendiline, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Fendiline.]
[M01AE04, fenoprofen, Fenoprofen may increase the neuroexcitatory activities of Levofloxacin.]
[N02AB03, fentanyl, Fentanyl may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Levofloxacin.]
[L01BB06, clofarabine, Clofarabine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N07AX03, cevimeline, Cevimeline may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[G04BD02, flavoxate, Levofloxacin may decrease the excretion rate of Flavoxate which could result in a higher serum level.]
[C01BC04, flecainide, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Flecainide.]
[N02BG04, floctafenine, Floctafenine may increase the neuroexcitatory activities of Levofloxacin.]
[J01CF05, floxacillin, The serum concentration of Levofloxacin can be increased when it is combined with Flucloxacillin.]
[J02AC01, fluconazole, The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Levofloxacin.]
[J02AX01, flucytosine, Flucytosine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[H02AA02, fludrocortisone, The risk or severity of tendinopathy can be increased when Fludrocortisone is combined with Levofloxacin.]
[V03AB25, flumazenil, Levofloxacin may decrease the excretion rate of Flumazenil which could result in a higher serum level.]
[D07XB01, flumethasone, The risk or severity of tendinopathy can be increased when Flumethasone is combined with Levofloxacin.]
[D07AC08, fluocinonide, The risk or severity of tendinopathy can be increased when Fluocinonide is combined with Levofloxacin.]
[H02AB03, fluocortolone, The risk or severity of tendinopathy can be increased when Fluocortolone is combined with Levofloxacin.]
[L01BC09, floxuridine, Floxuridine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[L01BC02, fluorouracil, The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Levofloxacin.]
[N06AB03, fluoxetine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Levofloxacin.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Flupentixol.]
[N05CD01, flurazepam, Flurazepam may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[S01BC04, flurbiprofen, Flurbiprofen may increase the neuroexcitatory activities of Levofloxacin.]
[N05AG01, fluspirilene, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Fluspirilene.]
[L02BB01, flutamide, Flutamide may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[S02AA17, fosfomycin, Fosfomycin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[L01BC03, tegafur, Levofloxacin may decrease the excretion rate of Tegafur which could result in a higher serum level.]
[C03CA01, furosemide, Furosemide may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CF04, eszopiclone, Eszopiclone may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Amisulpride.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Levofloxacin.]
[C08DA02, gallopamil, The risk or severity of QTc prolongation can be increased when Gallopamil is combined with Levofloxacin.]
[S01AD09, ganciclovir, Ganciclovir may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C10AB04, gemfibrozil, Levofloxacin may decrease the excretion rate of Gemfibrozil which could result in a higher serum level.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Degarelix is combined with Levofloxacin.]
[L01EA02, dasatinib, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Levofloxacin.]
[C01CA21, cafedrine, The metabolism of Cafedrine can be decreased when combined with Levofloxacin.]
[A10BJ02, liraglutide, The therapeutic efficacy of Liraglutide can be increased when used in combination with Levofloxacin.]
[N03AD03, methsuximide, The risk or severity of QTc prolongation can be increased when Methsuximide is combined with Levofloxacin.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Levofloxacin.]
[A10BB01, glyburide, The therapeutic efficacy of Glyburide can be increased when used in combination with Levofloxacin.]
[A10BB09, gliclazide, The therapeutic efficacy of Gliclazide can be increased when used in combination with Levofloxacin.]
[A10BB07, glipizide, The therapeutic efficacy of Glipizide can be increased when used in combination with Levofloxacin.]
[N05CM18, dexmedetomidine, Dexmedetomidine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C01BD04, dofetilide, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Dofetilide.]
[L01EX02, sorafenib, The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Levofloxacin.]
[C07AB09, esmolol, The risk or severity of QTc prolongation can be increased when Esmolol is combined with Levofloxacin.]
[M01CB04, aurothioglucose, Levofloxacin may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Levofloxacin may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[B01AA12, fluindione, The therapeutic efficacy of Fluindione can be increased when used in combination with Levofloxacin.]
[C09AA09, fosinopril, Fosinopril may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[S01EX01, guanethidine, Levofloxacin may decrease the excretion rate of Guanethidine which could result in a higher serum level.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Goserelin is combined with Levofloxacin.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Haloperidol.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Histrelin is combined with Levofloxacin.]
[N05AH04, quetiapine, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Quetiapine.]
[N06BX13, idebenone, Levofloxacin may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[A10AD05, insulin aspart, human, The therapeutic efficacy of Insulin aspart can be increased when used in combination with Levofloxacin.]
[M04AA01, allopurinol, Allopurinol may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C09CA01, losartan, The risk or severity of QTc prolongation can be increased when Losartan is combined with Levofloxacin.]
[B05CB03, magnesium citrate, Magnesium citrate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A12CC03, magnesium gluconate, Magnesium gluconate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[G03DC01, allylestrenol, Levofloxacin may decrease the excretion rate of Allylestrenol which could result in a higher serum level.]
[A07EC02, mesalamine, Mesalazine may increase the neuroexcitatory activities of Levofloxacin.]
[C01CE02, milrinone, Milrinone may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C08CA10, nilvadipine, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Nilvadipine.]
[M02AA26, nimesulide, Nimesulide may increase the neuroexcitatory activities of Levofloxacin.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Oxatomide.]
[C09AA04, perindopril, Perindopril may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C02DB02, hydralazine, Levofloxacin may decrease the excretion rate of Hydralazine which could result in a higher serum level.]
[C03AA03, hydrochlorothiazide, Hydrochlorothiazide may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[S02BA01, hydrocortisone, The risk or severity of tendinopathy can be increased when Hydrocortisone is combined with Levofloxacin.]
[D07AB02, hydrocortisone butyrate, The risk or severity of tendinopathy can be increased when Hydrocortisone butyrate is combined with Levofloxacin.]
[C03AA02, hydroflumethiazide, Hydroflumethiazide may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[B05XA17, potassium acetate, Levofloxacin may decrease the excretion rate of Potassium acetate which could result in a higher serum level.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Hydroxocobalamin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[G04BD06, propiverine, Levofloxacin may decrease the excretion rate of Propiverine which could result in a higher serum level.]
[P01BA02, hydroxychloroquine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Levofloxacin.]
[B05AA07, hetastarch, Levofloxacin may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Hydroxyzine.]
[R02AX02, ibuprofen, Ibuprofen may increase the neuroexcitatory activities of Levofloxacin.]
[B05XA08, sodium acetate, Levofloxacin may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[L01AA06, ifosfamide, Levofloxacin may decrease the excretion rate of Ifosfamide which could result in a higher serum level.]
[N06AA02, imipramine, The risk or severity of QTc prolongation can be increased when Imipramine is combined with Levofloxacin.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Terlipressin.]
[R01AD07, tixocortol, The risk or severity of tendinopathy can be increased when Tixocortol is combined with Levofloxacin.]
[M03BX02, tizanidine, The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Levofloxacin.]
[L01CE01, topotecan, The excretion of Topotecan can be decreased when combined with Levofloxacin.]
[C03BA11, indapamide, Indapamide may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC01, indomethacin, Indomethacin may increase the neuroexcitatory activities of Levofloxacin.]
[A16AX05, zinc acetate, Zinc acetate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A12CB02, zinc gluconate, Zinc gluconate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A11HA07, inositol, Levofloxacin may decrease the excretion rate of Inositol which could result in a higher serum level.]
[N06AX17, milnacipran, Levofloxacin may decrease the excretion rate of Milnacipran which could result in a higher serum level.]
[S01XA28, varenicline, Levofloxacin may decrease the excretion rate of Varenicline which could result in a higher serum level.]
[N01BB08, articaine, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Articaine.]
[A10BH01, sitagliptin, The therapeutic efficacy of Sitagliptin can be increased when used in combination with Levofloxacin.]
[N05BA12, alprazolam, Alprazolam may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N05CH02, ramelteon, Ramelteon may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Buclizine is combined with Levofloxacin.]
[A10BH02, vildagliptin, The therapeutic efficacy of Vildagliptin can be increased when used in combination with Levofloxacin.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Anagrelide.]
[C03BA02, quinethazone, Quinethazone may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB01, ipecac, Levofloxacin may decrease the excretion rate of Ipecac which could result in a higher serum level.]
[G04BE01, alprostadil, The excretion of Levofloxacin can be decreased when combined with Alprostadil.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Levofloxacin.]
[J04AC01, isoniazid, Isoniazid may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J05AX05, inosine pranobex, Levofloxacin may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[A10BJ01, exenatide, The therapeutic efficacy of Exenatide can be increased when used in combination with Levofloxacin.]
[C01DA14, isosorbide mononitrate, Isosorbide mononitrate may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[D10BA01, isotretinoin, Isotretinoin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[S01AA24, kanamycin, Levofloxacin may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[A02AB01, aluminum hydroxide, Aluminum hydroxide can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N01AX03, ketamine, Levofloxacin may decrease the excretion rate of Ketamine which could result in a higher serum level.]
[B01AC22, prasugrel, Levofloxacin may decrease the excretion rate of Prasugrel which could result in a higher serum level.]
[J02AB02, ketoconazole, The risk or severity of QTc prolongation can be increased when Ketoconazole is combined with Levofloxacin.]
[H02CA04, levoketoconazole, The excretion of Levofloxacin can be decreased when combined with Levoketoconazole.]
[N05AH03, olanzapine, The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Levofloxacin.]
[M02AA10, ketoprofen, Ketoprofen may increase the neuroexcitatory activities of Levofloxacin.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Mizolastine.]
[D10AX03, azelaic acid, Azelaic acid may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Levofloxacin.]
[M01AE11, tiaprofenic acid, Tiaprofenic acid may increase the neuroexcitatory activities of Levofloxacin.]
[C07AG01, labetalol, Labetalol may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Levofloxacin.]
[A06AD11, lactulose, The therapeutic efficacy of Lactulose can be decreased when used in combination with Levofloxacin.]
[A06AX03, lubiprostone, Lubiprostone may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C03CC01, ethacrynic acid, Etacrynic acid may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[J01CA11, amdinocillin, The serum concentration of Levofloxacin can be increased when it is combined with Amdinocillin.]
[J01CA08, amdinocillin pivoxil, The serum concentration of Levofloxacin can be increased when it is combined with Pivmecillinam.]
[S02DA01, lidocaine, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Lidocaine.]
[C08EX01, lidoflazine, The risk or severity of QTc prolongation can be increased when Lidoflazine is combined with Levofloxacin.]
[S01AA21, amikacin, Levofloxacin may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[C03DB01, amiloride, Amiloride may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[A07DA03, loperamide, The risk or severity of QTc prolongation can be increased when Loperamide is combined with Levofloxacin.]
[N05BA06, lorazepam, Lorazepam may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[B05XA11, magnesium chloride, Magnesium chloride can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[G04BX01, magnesium hydroxide, Magnesium hydroxide can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[A12CC10, magnesium oxide, Magnesium oxide can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[V04CC02, magnesium sulfate, Magnesium sulfate can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L01BA05, pralatrexate, Levofloxacin may decrease the excretion rate of Pralatrexate which could result in a higher serum level.]
[L01EA03, nilotinib, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Nilotinib.]
[V04CX04, mannitol, Mannitol may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA21, maprotiline, The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Levofloxacin.]
[C02BB01, mecamylamine, Mecamylamine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[M02AA18, meclofenamic acid, Meclofenamic acid may increase the neuroexcitatory activities of Levofloxacin.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Levofloxacin.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[N06DX01, memantine, Memantine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N02AB02, meperidine, Meperidine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N01BB03, mepivacaine, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Mepivacaine.]
[G04BX16, tiopronin, Levofloxacin may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Levofloxacin.]
[N05AX13, paliperidone, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Paliperidone.]
[A10BA02, metformin, The therapeutic efficacy of Metformin can be increased when used in combination with Levofloxacin.]
[A04AA04, dolasetron, The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Levofloxacin.]
[N07BC02, methadone, The risk or severity of QTc prolongation can be increased when Methadone is combined with Levofloxacin.]
[N06BA03, methamphetamine, Levofloxacin may decrease the excretion rate of Metamfetamine which could result in a higher serum level.]
[J05AF05, lamivudine, Lamivudine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[S01EC05, methazolamide, Methazolamide may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[H03BB02, methimazole, Methimazole may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[L01BA04, pemetrexed, Levofloxacin may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[L04AX03, methotrexate, Methotrexate may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N05AA02, methotrimeprazine, The risk or severity of QTc prolongation can be increased when Methotrimeprazine is combined with Levofloxacin.]
[D05BA02, methoxsalen, Methoxsalen may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C03AA08, methyclothiazide, Methyclothiazide may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AB01, methyldopa, Methyldopa may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[V04CG05, methylene blue, Levofloxacin may decrease the excretion rate of Methylene blue which could result in a higher serum level.]
[R03DA05, aminophylline, The metabolism of Aminophylline can be decreased when combined with Levofloxacin.]
[H02AB04, methylprednisolone, The risk or severity of tendinopathy can be increased when Methylprednisolone is combined with Levofloxacin.]
[D07AC14, methylprednisolone aceponate, The risk or severity of tendinopathy can be increased when Methylprednisolone aceponate is combined with Levofloxacin.]
[G03EK01, methyltestosterone, Levofloxacin may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.]
[A03FA01, metoclopramide, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Levofloxacin.]
[C03BA08, metolazone, Metolazone may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB02, metoprolol, Metoprolol may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Levofloxacin.]
[V04CD01, metyrapone, Metyrapone may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01CA10, mezlocillin, The serum concentration of Levofloxacin can be increased when it is combined with Mezlocillin.]
[N02BB03, aminopyrine, Aminophenazone may increase the neuroexcitatory activities of Levofloxacin.]
[N05CD08, midazolam, Midazolam may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[G03XB01, mifepristone, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Mifepristone.]
[J05AH01, zanamivir, Zanamivir may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01AA08, minocycline, The excretion of Levofloxacin can be decreased when combined with Minocycline.]
[L03AC01, aldesleukin, Aldesleukin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C01BD01, amiodarone, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Amiodarone.]
[N06AA09, amitriptyline, Levofloxacin may increase the QTc-prolonging activities of Amitriptyline.]
[A04AA05, palonosetron, Palonosetron may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[L04AB05, certolizumab pegol, Levofloxacin may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.]
[G04BA01, ammonium chloride, Levofloxacin may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.]
[L01EX03, pazopanib, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Pazopanib.]
[L04AA06, mycophenolic acid, The serum concentration of Mycophenolic acid can be decreased when it is combined with Levofloxacin.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Levofloxacin.]
[N06AA17, amoxapine, The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Levofloxacin.]
[C07AA12, nadolol, Levofloxacin may decrease the excretion rate of Nadolol which could result in a higher serum level.]
[N04BC04, ropinirole, The risk or severity of adverse effects can be increased when Levofloxacin is combined with Ropinirole.]
[J01CF06, nafcillin, The serum concentration of Levofloxacin can be increased when it is combined with Nafcillin.]
[V03AB15, naloxone, Levofloxacin may decrease the excretion rate of Naloxone which could result in a higher serum level.]
[N06BA01, amphetamine, Amphetamine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[M02AA12, naproxen, Naproxen may increase the neuroexcitatory activities of Levofloxacin.]
[A10BG01, troglitazone, The therapeutic efficacy of Troglitazone can be increased when used in combination with Levofloxacin.]
[N06AX21, duloxetine, Duloxetine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N04BX01, tolcapone, Tolcapone may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[S03AA01, neomycin, Levofloxacin may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[A10BX02, repaglinide, The therapeutic efficacy of Repaglinide can be increased when used in combination with Levofloxacin.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Levofloxacin.]
[B01AC17, tirofiban, Tirofiban may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N05AX14, iloperidone, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Iloperidone.]
[J02AA01, amphotericin B, Amphotericin B may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[S01AA19, ampicillin, The serum concentration of Levofloxacin can be increased when it is combined with Ampicillin.]
[L03AX16, plerixafor, Levofloxacin may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Levofloxacin may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, Levofloxacin may decrease the excretion rate of Desvenlafaxine which could result in a higher serum level.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C01CE01, inamrinone, Levofloxacin may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[C08CA04, nicardipine, The risk or severity of QTc prolongation can be increased when Nicardipine is combined with Levofloxacin.]
[C08CA05, nifedipine, The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Levofloxacin.]
[M02AA17, niflumic acid, Niflumic acid may increase the neuroexcitatory activities of Levofloxacin.]
[C08CA06, nimodipine, The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Levofloxacin.]
[C08CA07, nisoldipine, Nisoldipine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C08CA08, nitrendipine, The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Levofloxacin.]
[R07AX01, nitric oxide, Nitric Oxide may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01XE01, nitrofurantoin, The therapeutic efficacy of Levofloxacin can be decreased when used in combination with Nitrofurantoin.]
[N05CF03, zaleplon, Zaleplon may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N04BC05, pramipexole, Pramipexole may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C02DD01, nitroprusside, Nitroprusside can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Levofloxacin.]
[N06AA10, nortriptyline, The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Levofloxacin.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Levofloxacin.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Ofloxacin.]
[N02AA02, opium, Levofloxacin may decrease the excretion rate of Opium which could result in a higher serum level.]
[G04CA02, tamsulosin, Tamsulosin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01CF04, oxacillin, The serum concentration of Levofloxacin can be increased when it is combined with Oxacillin.]
[V08CB01, ferumoxsil, Ferumoxsil can cause a decrease in the absorption of Levofloxacin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N05BA04, oxazepam, Oxazepam may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Oxolinic acid is combined with Levofloxacin.]
[S01BC02, oxyphenbutazone, Oxyphenbutazone may increase the neuroexcitatory activities of Levofloxacin.]
[S01AA04, oxytetracycline, The excretion of Levofloxacin can be decreased when combined with Oxytetracycline.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Levofloxacin.]
[V04CH30, 4-aminohippuric acid, The excretion of Levofloxacin can be decreased when combined with Aminohippuric acid.]
[N05AH05, asenapine, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Asenapine.]
[J04AB30, capreomycin, Levofloxacin may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Papaverine is combined with Levofloxacin.]
[H02AB05, paramethasone, The risk or severity of tendinopathy can be increased when Paramethasone is combined with Levofloxacin.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Levofloxacin.]
[G04BD11, fesoterodine, Levofloxacin may decrease the excretion rate of Fesoterodine which could result in a higher serum level.]
[C07AA23, penbutolol, Levofloxacin may decrease the excretion rate of Penbutolol which could result in a higher serum level.]
[N05AG03, penfluridol, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Penfluridol.]
[S01AA14, penicillin G, The serum concentration of Levofloxacin can be increased when it is combined with Benzylpenicillin.]
[J01CE09, penicillin G procaine, The serum concentration of Levofloxacin can be increased when it is combined with Procaine benzylpenicillin.]
[J01CE02, penicillin V, The serum concentration of Levofloxacin can be increased when it is combined with Phenoxymethylpenicillin.]
[N05CA01, pentobarbital, Pentobarbital may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[L01XX08, pentostatin, Levofloxacin may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, The metabolism of Pentoxifylline can be decreased when combined with Levofloxacin.]
[C08EX02, perhexiline, The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Levofloxacin.]
[N02BE03, phenacetin, The excretion of Levofloxacin can be decreased when combined with Phenacetin.]
[G04BX06, phenazopyridine, Phenazopyridine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N06AF03, phenelzine, Phenelzine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[A10BA01, phenformin, The therapeutic efficacy of Phenformin can be increased when used in combination with Levofloxacin.]
[B01AA02, phenindione, The therapeutic efficacy of Phenindione can be increased when used in combination with Levofloxacin.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Levofloxacin.]
[B01AA04, phenprocoumon, The therapeutic efficacy of Phenprocoumon can be increased when used in combination with Levofloxacin.]
[V03AB36, phentolamine, Phentolamine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[M02AA01, phenylbutazone, Phenylbutazone may increase the neuroexcitatory activities of Levofloxacin.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Pipemidic acid is combined with Levofloxacin.]
[B02BA01, vitamin K1, Phylloquinone may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C08CX01, mibefradil, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Mibefradil.]
[N05AG02, pimozide, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Pimozide.]
[C07AA03, pindolol, Pindolol may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01CA12, piperacillin, The serum concentration of Levofloxacin can be increased when it is combined with Piperacillin.]
[J05AE01, saquinavir, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Saquinavir.]
[N06BX03, piracetam, Levofloxacin may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[S01BC06, piroxicam, Piroxicam may increase the neuroexcitatory activities of Levofloxacin.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Grepafloxacin.]
[J01CA02, pivampicillin, The serum concentration of Levofloxacin can be increased when it is combined with Pivampicillin.]
[A10BG02, rosiglitazone, The therapeutic efficacy of Rosiglitazone can be increased when used in combination with Levofloxacin.]
[C03AA05, polythiazide, Polythiazide may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[J05AE03, ritonavir, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Levofloxacin.]
[A10BH03, saxagliptin, The therapeutic efficacy of Saxagliptin can be increased when used in combination with Levofloxacin.]
[B05XA01, potassium chloride, Potassium chloride may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[A10AD04, insulin lispro, The therapeutic efficacy of Insulin lispro can be increased when used in combination with Levofloxacin.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Prajmaline is combined with Levofloxacin.]
[S03BA02, prednisolone, The risk or severity of tendinopathy can be increased when Prednisolone is combined with Levofloxacin.]
[H02AB07, prednisone, The risk or severity of tendinopathy can be increased when Prednisone is combined with Levofloxacin.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Antazoline.]
[C01DX02, prenylamine, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Prenylamine.]
[N01BB04, prilocaine, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Prilocaine.]
[P01BA03, primaquine, The risk or severity of QTc prolongation can be increased when Primaquine is combined with Levofloxacin.]
[M04AB01, probenecid, The serum concentration of Levofloxacin can be increased when it is combined with Probenecid.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Probucol.]
[C01BA02, procainamide, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Procainamide.]
[S01HA05, procaine, The risk or severity of methemoglobinemia can be increased when Levofloxacin is combined with Procaine.]
[C10AB05, fenofibrate, Fenofibrate may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N05AB04, prochlorperazine, The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Levofloxacin.]
[N05AA03, promazine, The risk or severity of QTc prolongation can be increased when Promazine is combined with Levofloxacin.]
[R06AD02, promethazine, The risk or severity of QTc prolongation can be increased when Promethazine is combined with Levofloxacin.]
[C01BC03, propafenone, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Propafenone.]
[A03AB05, propantheline, Propantheline may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Romidepsin.]
[N01AX10, propofol, The risk or severity of QTc prolongation can be increased when Propofol is combined with Levofloxacin.]
[C07AA05, propranolol, Propranolol may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[N02CC04, rizatriptan, Rizatriptan may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[B01AC09, epoprostenol, Levofloxacin may decrease the excretion rate of Epoprostenol which could result in a higher serum level.]
[N06AA11, protriptyline, The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Levofloxacin.]
[N05AX12, aripiprazole, The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Levofloxacin.]
[N07XX07, dalfampridine, Levofloxacin may decrease the excretion rate of Dalfampridine which could result in a higher serum level.]
[P02CC01, pyrantel, Levofloxacin may decrease the excretion rate of Pyrantel which could result in a higher serum level.]
[J04AK01, pyrazinamide, Pyrazinamide may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[R06AC01, pyrilamine, The risk or severity of QTc prolongation can be increased when Mepyramine is combined with Levofloxacin.]
[P01BD01, pyrimethamine, The excretion of Levofloxacin can be decreased when combined with Pyrimethamine.]
[C01BA01, quinidine, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Quinidine.]
[P01BC01, quinine, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Quinine.]
[A02BA02, ranitidine, Ranitidine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[C02AA02, reserpine, Reserpine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J05AP01, ribavirin, Ribavirin may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[S01XA26, riboflavin, The excretion of Levofloxacin can be decreased when combined with Riboflavin.]
[J04AB02, rifampin, The excretion of Levofloxacin can be decreased when combined with Rifampicin.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Levofloxacin.]
[N02BA05, salicylamide, Salicylamide may increase the neuroexcitatory activities of Levofloxacin.]
[A07EC01, sulfasalazine, Sulfasalazine may increase the neuroexcitatory activities of Levofloxacin.]
[S01BC08, salicylic acid, Salicylic acid may increase the neuroexcitatory activities of Levofloxacin.]
[N05CA06, secobarbital, Secobarbital may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[J01GB08, sisomicin, Levofloxacin may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Levofloxacin may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[V04CC01, sorbitol, Levofloxacin may decrease the excretion rate of Sorbitol which could result in a higher serum level.]
[C07AA07, sotalol, The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Sotalol.]
[C03DA01, spironolactone, Spironolactone may increase the excretion rate of Levofloxacin which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AL01, sulpiride, QT prolonging agents - QT prolonging agents]
[N05AC02, thioridazine, QT prolonging agents - QT prolonging agents]
[L01EX04, vandetanib, QT prolonging agents - QT prolonging agents]
[N06DA02, donepezil, QT prolonging agents - QT prolonging agents]
[S01AE07, moxifloxacin, QT prolonging agents - QT prolonging agents]
[C08EA02, bepridil, QT prolonging agents - QT prolonging agents]
[L01XX27, arsenic trioxide, QT prolonging agents - QT prolonging agents]
[J01MA09, sparfloxacin, QT prolonging agents - QT prolonging agents]
[S01AA26, azithromycin, QT prolonging agents - QT prolonging agents]
[B01AC23, cilostazol, QT prolonging agents - QT prolonging agents]
[J01FA09, clarithromycin, QT prolonging agents - QT prolonging agents]
[S01AE06, gatifloxacin, QT prolonging agents - QT prolonging agents]
[C01BD07, dronedarone, QT prolonging agents - QT prolonging agents]
[L01DB04, aclarubicin, QT prolonging agents - QT prolonging agents]
[P01BA01, chloroquine, QT prolonging agents - QT prolonging agents]
[N05AA01, chlorpromazine, QT prolonging agents - QT prolonging agents]
[N05AF03, chlorprothixene, QT prolonging agents - QT prolonging agents]
[S03AA07, ciprofloxacin, QT prolonging agents - QT prolonging agents]
[N06AB04, citalopram, QT prolonging agents - QT prolonging agents]
[L01EB10, mobocertinib, QT prolonging agents - QT prolonging agents]
[A04AA01, ondansetron, QT prolonging agents - QT prolonging agents]
[S02DA02, cocaine, QT prolonging agents - QT prolonging agents]
[C01BA13, hydroquinidine, QT prolonging agents - QT prolonging agents]
[P01CB01, meglumine antimoniate, QT prolonging agents - QT prolonging agents]
[L01XA03, oxaliplatin, QT prolonging agents - QT prolonging agents]
[A03FA02, cisapride, QT prolonging agents - QT prolonging agents]
[C01BA03, disopyramide, QT prolonging agents - QT prolonging agents]
[A03FA03, domperidone, QT prolonging agents - QT prolonging agents]
[N01AB08, sevoflurane, QT prolonging agents - QT prolonging agents]
[N05AD08, droperidol, QT prolonging agents - QT prolonging agents]
[N05AL02, sultopride, QT prolonging agents - QT prolonging agents]
[G04BD05, terodiline, QT prolonging agents - QT prolonging agents]
[S01AA17, erythromycin, QT prolonging agents - QT prolonging agents]
[C01BD05, ibutilide, QT prolonging agents - QT prolonging agents]
[N05AE03, sertindole, QT prolonging agents - QT prolonging agents]
[R06AX11, astemizole, QT prolonging agents - QT prolonging agents]
[R06AX12, terfenadine, QT prolonging agents - QT prolonging agents]
[C01BC04, flecainide, QT prolonging agents - QT prolonging agents]
[J02AC01, fluconazole, QT prolonging agents - QT prolonging agents]
[C01BD04, dofetilide, QT prolonging agents - QT prolonging agents]
[P01BX01, halofantrine, QT prolonging agents - QT prolonging agents]
[N05AD01, haloperidol, QT prolonging agents - QT prolonging agents]
[P01BA02, hydroxychloroquine, QT prolonging agents - QT prolonging agents]
[H01BA04, terlipressin, QT prolonging agents - QT prolonging agents]
[L01XX35, anagrelide, QT prolonging agents - QT prolonging agents]
[N05AC03, mesoridazine, QT prolonging agents - QT prolonging agents]
[N07BC02, methadone, QT prolonging agents - QT prolonging agents]
[N05AA02, methotrimeprazine, QT prolonging agents - QT prolonging agents]
[C01BD01, amiodarone, QT prolonging agents - QT prolonging agents]
[N05AG02, pimozide, QT prolonging agents - QT prolonging agents]
[J01MA11, grepafloxacin, QT prolonging agents - QT prolonging agents]
[C10AX02, probucol, QT prolonging agents - QT prolonging agents]
[C01BA02, procainamide, QT prolonging agents - QT prolonging agents]
[N01AX10, propofol, QT prolonging agents - QT prolonging agents]
[C01BA01, quinidine, QT prolonging agents - QT prolonging agents]
[J01FA06, roxithromycin, QT prolonging agents - QT prolonging agents]
[C07AA07, sotalol, QT prolonging agents - QT prolonging agents]
